{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:30:52Z","timestamp":1794000652345,"version":"4.8.0"},"reference-count":666,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M771439"],"award-info":[{"award-number":["2025M771439"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82504345"],"award-info":[{"award-number":["82504345"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373513"],"award-info":[{"award-number":["82373513"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1105300"],"award-info":[{"award-number":["2022YFA1105300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2503700"],"award-info":[{"award-number":["2022YFC2503700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014219","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82225040"],"award-info":[{"award-number":["82225040"]}],"id":[{"id":"10.13039\/501100014219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02477-6","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:37:50Z","timestamp":1760445470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["Turning cold tumors into hot tumors to ignite immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuan-Tong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Juan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Bo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"2477_CR1","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42:1825\u201363.","journal-title":"Cancer Cell"},{"key":"2477_CR2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"2477_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin H, Zhou Z, Shi R, Mai Y, Xu Y, Peng F, et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 2025;18:62.","journal-title":"J Hematol Oncol"},{"key":"2477_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24:399\u2013416.","journal-title":"Nat Rev Immunol"},{"key":"2477_CR5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"2477_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"2477_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov. 2022;21:529\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"2477_CR8","first-page":"187","volume":"74","author":"G Kroemer","year":"2024","unstructured":"Kroemer G, Chan TA, Eggermont AMM, Galluzzi L. Immunosurveillance in clinical cancer management. CA Cancer J Clin. 2024;74:187\u2013202.","journal-title":"CA Cancer J Clin"},{"key":"2477_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.trecan.2024.11.011","volume":"11","author":"K Ma","year":"2025","unstructured":"Ma K, Wang L, Li W, Tang T, Ma B, Zhang L. Turning cold into hot: emerging strategies to fire up the tumor microenvironment. Trends Cancer. 2025;11:117\u201334.","journal-title":"Trends Cancer"},{"key":"2477_CR10","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365\u201386.","journal-title":"Theranostics"},{"key":"2477_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.343","volume":"4","author":"L Wang","year":"2023","unstructured":"Wang L, Geng H, Liu Y, Liu L, Chen Y, Wu F, et al. Hot and cold tumors: Immunological features and the therapeutic strategies. MedComm. 2023;4:e343.","journal-title":"MedComm"},{"key":"2477_CR13","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205.","journal-title":"Immunity"},{"key":"2477_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"key":"2477_CR15","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res. 2016;22:1865\u201374.","journal-title":"Clin Cancer Res"},{"key":"2477_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud JL, Houel A, Panouillot M, Riffard C, Dieu-Nosjean MC. Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer. 2024;24:629\u201346.","journal-title":"Nat Rev Cancer"},{"key":"2477_CR17","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer. 2023;129:1212\u201324.","journal-title":"Br J Cancer"},{"key":"2477_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662\u201380.","journal-title":"Nat Rev Cancer"},{"key":"2477_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330.","journal-title":"Nature"},{"key":"2477_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138.","journal-title":"Nat Immunol"},{"key":"2477_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","volume":"27","author":"I Vitale","year":"2021","unstructured":"Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27:212\u201324.","journal-title":"Nat Med"},{"key":"2477_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48\u201361.","journal-title":"Cell"},{"key":"2477_CR23","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259-71.e11.","journal-title":"Cell"},{"key":"2477_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02608-0","volume":"7","author":"C Ritter","year":"2017","unstructured":"Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, et al. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep. 2017;7:2290.","journal-title":"Sci Rep"},{"key":"2477_CR25","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","volume":"12","author":"V Gambacorta","year":"2022","unstructured":"Gambacorta V, Beretta S, Ciccimarra M, Zito L, Giannetti K, Andrisani A, et al. Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse. Cancer Discov. 2022;12:1449\u201361.","journal-title":"Cancer Discov"},{"key":"2477_CR26","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Takata K, B\u00e9guelin W, Duns G, Mottok A, Farinha P, et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9:546\u201363.","journal-title":"Cancer Discov"},{"key":"2477_CR27","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017;20:854\u201367.","journal-title":"Cell Rep"},{"key":"2477_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100\u20135.","journal-title":"Nature"},{"key":"2477_CR29","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.7150\/thno.103494","volume":"15","author":"X Xing","year":"2025","unstructured":"Xing X, Li XQ, Yin SQ, Ma HT, Xiao SY, Tulamaiti A, et al. OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-I. Theranostics. 2025;15:2104\u201320.","journal-title":"Theranostics"},{"key":"2477_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax7881","volume":"6","author":"MZ Noman","year":"2020","unstructured":"Noman MZ, Parpal S, Van Moer K, Xiao M, Yu Y, Viklund J, et al. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1\/PD-L1 immunotherapy. Sci Adv. 2020;6:eaax7881.","journal-title":"Sci Adv"},{"key":"2477_CR31","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1016\/j.cell.2024.09.048","volume":"187","author":"L Herhaus","year":"2024","unstructured":"Herhaus L, Gestal-Mato U, Eapen VV, Ma\u010dinkovi\u0107 I, Bailey HJ, Prieto-Garcia C, et al. IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion. Cell. 2024;187:7285-302.e29.","journal-title":"Cell"},{"key":"2477_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693\u20138.","journal-title":"Nature"},{"key":"2477_CR33","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen X, Lu Q, Zhou H, Liu J, Nadorp B, Lasry A, et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell. 2023;186:3903-20.e21.","journal-title":"Cell"},{"key":"2477_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12967-024-04938-w","volume":"22","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Xia Y, Zhang L, Jiang Y, Liu M, et al. Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects. J Transl Med. 2024;22:130.","journal-title":"J Transl Med"},{"key":"2477_CR35","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018;172:1022-37.e14.","journal-title":"Cell"},{"key":"2477_CR36","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","volume":"27","author":"T Cascone","year":"2018","unstructured":"Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018;27:977-87.e4.","journal-title":"Cell Metab"},{"key":"2477_CR37","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/j.immuni.2023.10.001","volume":"56","author":"Y Hou","year":"2023","unstructured":"Hou Y, Wang Z, Liu P, Wei X, Zhang Z, Fan S, et al. SMPDL3A is a cGAMP-degrading enzyme induced by LXR-mediated lipid metabolism to restrict cGAS-STING DNA sensing. Immunity. 2023;56:2492-507.e10.","journal-title":"Immunity"},{"key":"2477_CR38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313693120","volume":"120","author":"S Wang","year":"2023","unstructured":"Wang S, B\u00f6hnert V, Joseph AJ, Sudaryo V, Skariah G, Swinderman JT, et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer. Proc Natl Acad Sci U S A. 2023;120:e2313693120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119189119","volume":"119","author":"JA Carozza","year":"2022","unstructured":"Carozza JA, Cordova AF, Brown JA, AlSaif Y, B\u00f6hnert V, Cao X, et al. ENPP1\u2019s regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling. Proc Natl Acad Sci U S A. 2022;119:e2119189119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001375","volume":"2","author":"MP Chao","year":"2010","unstructured":"Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2:63ra94.","journal-title":"Sci Transl Med"},{"key":"2477_CR41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ccell.2020.12.023","volume":"39","author":"H Lin","year":"2021","unstructured":"Lin H, Kryczek I, Li S, Green MD, Ali A, Hamasha R, et al. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer Cell. 2021;39:480-93.e6.","journal-title":"Cancer Cell"},{"key":"2477_CR42","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1016\/j.cell.2021.05.021","volume":"184","author":"E Giampazolias","year":"2021","unstructured":"Giampazolias E, Schulz O, Lim KHJ, Rogers NC, Chakravarty P, Srinivasan N, et al. Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell. 2021;184:4016-31.e22.","journal-title":"Cell"},{"key":"2477_CR43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54:859\u201374.","journal-title":"Immunity"},{"key":"2477_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","volume":"24","author":"TR Mempel","year":"2024","unstructured":"Mempel TR, Lill JK, Altenburger LM. How chemokines organize the tumour microenvironment. Nat Rev Cancer. 2024;24:28\u201350.","journal-title":"Nat Rev Cancer"},{"key":"2477_CR45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"2477_CR46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527:249\u201353.","journal-title":"Nature"},{"key":"2477_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0125-1","volume":"4","author":"I Siddiqui","year":"2016","unstructured":"Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine\/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer. 2016;4:21.","journal-title":"J Immunother Cancer"},{"key":"2477_CR48","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, et al. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. Immunity. 2019;50:1498-512.e5.","journal-title":"Immunity"},{"key":"2477_CR49","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","volume":"56","author":"MA Moreno Ayala","year":"2023","unstructured":"Moreno Ayala MA, Campbell TF, Zhang C, Dahan N, Bockman A, Prakash V, et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity. 2023;56:1613-30.e5.","journal-title":"Immunity"},{"key":"2477_CR50","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.immuni.2025.06.005","volume":"58","author":"DB Mahat","year":"2025","unstructured":"Mahat DB, Kumra H, Castro SA, Metcalf E, Nguyen K, Morisue R, et al. Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer. Immunity. 2025;58:1688-705.e9.","journal-title":"Immunity"},{"key":"2477_CR51","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1158\/2326-6066.CIR-16-0188","volume":"4","author":"T Chao","year":"2016","unstructured":"Chao T, Furth EE, Vonderheide RH. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res. 2016;4:968\u201382.","journal-title":"Cancer Immunol Res"},{"key":"2477_CR52","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","volume":"52","author":"\u00c1 Teijeira","year":"2020","unstructured":"Teijeira \u00c1, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, et al. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity. 2020;52:856-71.e8.","journal-title":"Immunity"},{"key":"2477_CR53","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ijc.28770","volume":"135","author":"I Mishalian","year":"2014","unstructured":"Mishalian I, Bayuh R, Eruslanov E, Michaeli J, Levy L, Zolotarov L, et al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17\u2013a new mechanism of impaired antitumor immunity. Int J Cancer. 2014;135:1178\u201386.","journal-title":"Int J Cancer"},{"key":"2477_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024;8:31.","journal-title":"NPJ Precis Oncol"},{"key":"2477_CR55","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.celrep.2018.04.007","volume":"23","author":"EN Arwert","year":"2018","unstructured":"Arwert EN, Harney AS, Entenberg D, Wang Y, Sahai E, Pollard JW, et al. A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation. Cell Rep. 2018;23:1239\u201348.","journal-title":"Cell Rep"},{"key":"2477_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9:176.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01187-w","author":"E Lanitis","year":"2025","unstructured":"Lanitis E, Irving M, Coukos G. Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy. Nat Rev Immunol. 2025. https:\/\/doi.org\/10.1038\/s41577-025-01187-w.","journal-title":"Nat Rev Immunol"},{"key":"2477_CR58","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","volume":"24","author":"S Guelfi","year":"2024","unstructured":"Guelfi S, Hodivala-Dilke K, Bergers G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat Rev Cancer. 2024;24:655\u201375.","journal-title":"Nat Rev Cancer"},{"key":"2477_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37807-z","volume":"14","author":"DJ Kim","year":"2023","unstructured":"Kim DJ, Anandh S, Null JL, Przanowski P, Bhatnagar S, Kumar P, et al. Priming a vascular-selective cytokine response permits CD8(+) T-cell entry into tumors. Nat Commun. 2023;14:2122.","journal-title":"Nat Commun"},{"key":"2477_CR60","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","volume":"178","author":"C Bouzin","year":"2007","unstructured":"Bouzin C, Brouet A, De Vriese J, Dewever J, Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007;178:1505\u201311.","journal-title":"J Immunol"},{"key":"2477_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm1699","volume":"14","author":"RJ Buckanovich","year":"2008","unstructured":"Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14:28\u201336.","journal-title":"Nat Med"},{"key":"2477_CR62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607\u201315.","journal-title":"Nat Med"},{"key":"2477_CR63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","volume":"33","author":"E Lanitis","year":"2015","unstructured":"Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol. 2015;33:55\u201363.","journal-title":"Curr Opin Immunol"},{"key":"2477_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu Q, Zhu Y, Mei J, Liu Y, Zhou G. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. 2025;18:65.","journal-title":"J Hematol Oncol"},{"key":"2477_CR65","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI74725","volume":"125","author":"Y Chen","year":"2015","unstructured":"Chen Y, Terajima M, Yang Y, Sun L, Ahn YH, Pankova D, et al. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest. 2015;125:1147\u201362.","journal-title":"J Clin Invest"},{"key":"2477_CR66","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139:891\u2013906.","journal-title":"Cell"},{"key":"2477_CR67","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012;122:899\u2013910.","journal-title":"J Clin Invest"},{"key":"2477_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00714-6","volume":"12","author":"Z Guo","year":"2024","unstructured":"Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L, et al. Tumor microenvironment and immunotherapy for triple-negative breast cancer. Biomark Res. 2024;12:166.","journal-title":"Biomark Res"},{"key":"2477_CR69","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.ccr.2007.04.020","volume":"11","author":"JD Shields","year":"2007","unstructured":"Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell. 2007;11:526\u201338.","journal-title":"Cancer Cell"},{"key":"2477_CR70","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41416-021-01680-8","volume":"126","author":"B Darvishi","year":"2022","unstructured":"Darvishi B, Eisavand MR, Majidzadeh AK, Farahmand L. Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance. Br J Cancer. 2022;126:1253\u201363.","journal-title":"Br J Cancer"},{"key":"2477_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113745","volume":"155","author":"JR Chen","year":"2022","unstructured":"Chen JR, Zhao JT, Xie ZZ. Integrin-mediated cancer progression as a specific target in clinical therapy. Biomed Pharmacother. 2022;155:113745.","journal-title":"Biomed Pharmacother"},{"key":"2477_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18298-8","volume":"11","author":"DH Peng","year":"2020","unstructured":"Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, et al. Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion. Nat Commun. 2020;11:4520.","journal-title":"Nat Commun"},{"key":"2477_CR73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178540","volume":"134","author":"L Pang","year":"2024","unstructured":"Pang L, Zhou F, Liu Y, Ali H, Khan F, Heimberger AB, et al. Epigenetic regulation of tumor immunity. J Clin Invest. 2024;134:e178540.","journal-title":"J Clin Invest"},{"key":"2477_CR74","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-0296","volume":"14","author":"M Esteller","year":"2024","unstructured":"Esteller M, Dawson MA, Kadoch C, Rassool FV, Jones PA, Baylin SB. The epigenetic hallmarks of cancer. Cancer Discov. 2024;14:1783\u2013809.","journal-title":"Cancer Discov"},{"key":"2477_CR75","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","volume":"595","author":"GK Griffin","year":"2021","unstructured":"Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021;595:309\u201314.","journal-title":"Nature"},{"key":"2477_CR76","doi-asserted-by":"publisher","first-page":"eaaz6804","DOI":"10.1126\/scitranslmed.aaz6804","volume":"13","author":"W Yang","year":"2021","unstructured":"Yang W, Feng Y, Zhou J, Cheung OK, Cao J, Wang J, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med. 2021;13:eaaz6804.","journal-title":"Sci Transl Med"},{"key":"2477_CR77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025840118","volume":"118","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, et al. Activation of NF-\u03baB and p300\/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A. 2021;118:e2025840118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36:385-401.e8.","journal-title":"Cancer Cell"},{"key":"2477_CR79","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-021-03994-2","volume":"598","author":"SM Zhang","year":"2021","unstructured":"Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, et al. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature. 2021;598:682\u20137.","journal-title":"Nature"},{"key":"2477_CR80","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41586-023-06254-7","volume":"619","author":"J Li","year":"2023","unstructured":"Li J, Lan Z, Liao W, Horner JW, Xu X, Liu J, et al. Histone demethylase KDM5D upregulation drives sex differences in colon cancer. Nature. 2023;619:632\u20139.","journal-title":"Nature"},{"key":"2477_CR81","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37:1012\u201327.","journal-title":"Trends Genet"},{"key":"2477_CR82","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/j.molcel.2022.05.029","volume":"82","author":"S Murakami","year":"2022","unstructured":"Murakami S, Jaffrey SR. Hidden codes in mRNA: control of gene expression by m(6)A. Mol Cell. 2022;82:2236\u201351.","journal-title":"Mol Cell"},{"key":"2477_CR83","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.chembiol.2023.09.001","volume":"31","author":"H Yu","year":"2024","unstructured":"Yu H, Liu J, Bu X, Ma Z, Yao Y, Li J, et al. Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy. Cell Chem Biol. 2024;31:776-91.e7.","journal-title":"Cell Chem Biol"},{"key":"2477_CR84","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","volume":"163","author":"H Chen","year":"2022","unstructured":"Chen H, Pan Y, Zhou Q, Liang C, Wong C-C, Zhou Y, et al. METTL3 inhibits antitumor immunity by targeting m6A-BHLHE41-CXCL1\/CXCR2 axis to promote colorectal cancer. Gastroenterology. 2022;163:891\u2013907.","journal-title":"Gastroenterology"},{"key":"2477_CR85","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/cac2.12546","volume":"44","author":"Y Tang","year":"2024","unstructured":"Tang Y, Cui G, Liu H, Han Y, Cai C, Feng Z, et al. Converting \u201ccold\u201d to \u201chot\u201d: epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells. Cancer Commun. 2024;44:601\u201336.","journal-title":"Cancer Commun"},{"key":"2477_CR86","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41556-020-0491-2","volume":"22","author":"J Nishida","year":"2020","unstructured":"Nishida J, Momoi Y, Miyakuni K, Tamura Y, Takahashi K, Koinuma D, et al. Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis. Nat Cell Biol. 2020;22:465\u201375.","journal-title":"Nat Cell Biol"},{"key":"2477_CR87","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1038\/s41467-022-34871-9","volume":"13","author":"N Li","year":"2022","unstructured":"Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J, et al. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun. 2022;13:7281.","journal-title":"Nat Commun"},{"key":"2477_CR88","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12967-020-02553-z","volume":"18","author":"HH Ni","year":"2020","unstructured":"Ni HH, Zhang L, Huang H, Dai SQ, Li J. Connecting METTL3 and intratumoural CD33(+) MDSCs in predicting clinical outcome in cervical cancer. J Transl Med. 2020;18:393.","journal-title":"J Transl Med"},{"key":"2477_CR89","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","volume":"41","author":"L Wang","year":"2023","unstructured":"Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023;41:1294-308.e8.","journal-title":"Cancer Cell"},{"key":"2477_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.12.043","author":"Y Liu","year":"2025","unstructured":"Liu Y, Tan H, Dai J, Lin J, Zhao K, Hu H, et al. Targeting macrophages in cancer immunotherapy: Frontiers and challenges. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2024.12.043.","journal-title":"J Adv Res"},{"key":"2477_CR91","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai S, Itahashi K, Nishikawa H. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat Rev Clin Oncol. 2024;21:337\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"2477_CR92","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol. 2024;21:147\u201364.","journal-title":"Nat Rev Clin Oncol"},{"key":"2477_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216193","volume":"563","author":"YY Wang","year":"2023","unstructured":"Wang YY, Wu ZZ, Huang CF, Sun ZJ. Tumor-host colluding through erythroid progenitor cells: mechanisms and opportunities. Cancer Lett. 2023;563:216193.","journal-title":"Cancer Lett"},{"key":"2477_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02242-7","volume":"10","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Shen G, Zhou X, Li J. Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct Target Ther. 2025;10:178.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR95","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-17-3841","volume":"78","author":"X Wang","year":"2018","unstructured":"Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T, et al. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN\/PI3K\u03b3 to promote pancreatic cancer metastasis. Cancer Res. 2018;78:4586\u201398.","journal-title":"Cancer Res"},{"key":"2477_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03664-1","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu J, Zhang J, Zhang Z, Gao Z, Qi Y, Qiu W, et al. Hypoxic glioma-derived exosomes promote M2-like macrophage polarization by enhancing autophagy induction. Cell Death Dis. 2021;12:373.","journal-title":"Cell Death Dis"},{"key":"2477_CR97","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1016\/j.ymthe.2022.01.046","volume":"30","author":"Z Xu","year":"2022","unstructured":"Xu Z, Chen Y, Ma L, Chen Y, Liu J, Guo Y, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol Ther. 2022;30:3133\u201354.","journal-title":"Mol Ther"},{"key":"2477_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00991-2","volume":"13","author":"S Zhao","year":"2020","unstructured":"Zhao S, Mi Y, Guan B, Zheng B, Wei P, Gu Y, et al. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J Hematol Oncol. 2020;13:156.","journal-title":"J Hematol Oncol"},{"key":"2477_CR99","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","volume":"599","author":"B Zhang","year":"2021","unstructured":"Zhang B, Vogelzang A, Miyajima M, Sugiura Y, Wu Y, Chamoto K, et al. B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity. Nature. 2021;599:471\u20136.","journal-title":"Nature"},{"key":"2477_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6:75.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR101","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10555-025-10269-z","volume":"44","author":"A Ooki","year":"2025","unstructured":"Ooki A, Osumi H, Shimozaki K, Yamaguchi K. Novel immunotherapy for gastric cancer: targeting the CD47-SIRP\u03b1 axis. Cancer Metastasis Rev. 2025;44:52.","journal-title":"Cancer Metastasis Rev"},{"key":"2477_CR102","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139.","journal-title":"Nature"},{"key":"2477_CR103","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76\u201384.","journal-title":"Nat Immunol"},{"key":"2477_CR104","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392\u20136.","journal-title":"Nature"},{"key":"2477_CR105","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","volume":"53","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, et al. An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity. 2020;53:187-203.e8.","journal-title":"Immunity"},{"key":"2477_CR106","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aav3937","volume":"5","author":"E Sugiyama","year":"2020","unstructured":"Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 2020;5:eaav3937.","journal-title":"Sci Immunol"},{"key":"2477_CR107","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226\u201330.","journal-title":"Nature"},{"key":"2477_CR108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"M Tekguc","year":"2021","unstructured":"Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S. Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci U S A. 2021;118:e2023739118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR109","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276:121\u201344.","journal-title":"Immunol Rev"},{"key":"2477_CR110","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1038\/s41467-020-17811-3","volume":"11","author":"G de Streel","year":"2020","unstructured":"de Streel G, Bertrand C, Chalon N, Li\u00e9nart S, Bricard O, Lecomte S, et al. Selective inhibition of TGF-\u03b21 produced by GARP-expressing Tregs overcomes resistance to PD-1\/PD-L1 blockade in cancer. Nat Commun. 2020;11:4545.","journal-title":"Nat Commun"},{"key":"2477_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, S\u00f6derlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE. 2013;8:e55818.","journal-title":"PLoS ONE"},{"key":"2477_CR112","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781\u201390.","journal-title":"J Exp Med"},{"key":"2477_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/srep39296","volume":"6","author":"T Iwata","year":"2016","unstructured":"Iwata T, Kondo Y, Kimura O, Morosawa T, Fujisaka Y, Umetsu T, et al. PD-L1(+)MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. Sci Rep. 2016;6:39296.","journal-title":"Sci Rep"},{"key":"2477_CR114","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1073\/pnas.1612920114","volume":"114","author":"V Prima","year":"2017","unstructured":"Prima V, Kaliberova LN, Kaliberov S, Curiel DT, Kusmartsev S. COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc Natl Acad Sci U S A. 2017;114:1117\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR115","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","volume":"64","author":"PC Rodriguez","year":"2004","unstructured":"Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase i production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839\u201349.","journal-title":"Cancer Res"},{"key":"2477_CR116","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","volume":"190","author":"J Yu","year":"2013","unstructured":"Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190:3783\u201397.","journal-title":"J Immunol"},{"key":"2477_CR117","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","volume":"182","author":"CA Corzo","year":"2009","unstructured":"Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182:5693\u2013701.","journal-title":"J Immunol"},{"key":"2477_CR118","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/762825","volume":"2012","author":"T Fiaschi","year":"2012","unstructured":"Fiaschi T, Chiarugi P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol. 2012;2012:762825.","journal-title":"Int J Cell Biol"},{"key":"2477_CR119","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.4049\/jimmunol.160.12.5729","volume":"160","author":"RM Bingisser","year":"1998","unstructured":"Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3\/STAT5 signaling pathway. J Immunol. 1998;160:5729\u201334.","journal-title":"J Immunol"},{"key":"2477_CR120","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-17-0691","volume":"24","author":"A Stiff","year":"2018","unstructured":"Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, et al. Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. Clin Cancer Res. 2018;24:1891\u2013904.","journal-title":"Clin Cancer Res"},{"key":"2477_CR121","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ccell.2022.09.001","volume":"40","author":"EN Tcyganov","year":"2022","unstructured":"Tcyganov EN, Sanseviero E, Marvel D, Beer T, Tang HY, Hembach P, et al. Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Cancer Cell. 2022;40:1173-89.e6.","journal-title":"Cancer Cell"},{"key":"2477_CR122","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/2326-6066.CIR-19-0240","volume":"7","author":"C Lee-Chang","year":"2019","unstructured":"Lee-Chang C, Rashidi A, Miska J, Zhang P, Pituch KC, Hou D, et al. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma. Cancer Immunol Res. 2019;7:1928\u201343.","journal-title":"Cancer Immunol Res"},{"key":"2477_CR123","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1158\/0008-5472.CAN-14-3077","volume":"75","author":"M Bodogai","year":"2015","unstructured":"Bodogai M, Moritoh K, Lee-Chang C, Hollander CM, Sherman-Baust CA, Wersto RP, et al. Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. Cancer Res. 2015;75:3456\u201365.","journal-title":"Cancer Res"},{"key":"2477_CR124","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00262-025-03973-w","volume":"74","author":"R Ye","year":"2025","unstructured":"Ye R, Li S, Li Y, Shi K, Li L. Revealing the role of regulatory b cells in cancer: development, function and treatment significance. Cancer Immunol Immunother. 2025;74:125.","journal-title":"Cancer Immunol Immunother"},{"key":"2477_CR125","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/ijc.35102","volume":"155","author":"SR Li","year":"2024","unstructured":"Li SR, Wu ZZ, Yu HJ, Sun ZJ. Targeting erythroid progenitor cells for cancer immunotherapy. Int J Cancer. 2024;155:1928\u201338.","journal-title":"Int J Cancer"},{"key":"2477_CR126","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1541-7786.MCR-20-0746","volume":"19","author":"Y Sano","year":"2021","unstructured":"Sano Y, Yoshida T, Choo MK, Jim\u00e9nez-Andrade Y, Hill KR, Georgopoulos K, et al. Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules. Mol Cancer Res. 2021;19:507\u201315.","journal-title":"Mol Cancer Res"},{"key":"2477_CR127","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-018-0205-5","volume":"24","author":"L Zhao","year":"2018","unstructured":"Zhao L, He R, Long H, Guo B, Jia Q, Qin D, et al. Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells. Nat Med. 2018;24:1536\u201344.","journal-title":"Nat Med"},{"key":"2477_CR128","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2020.12.003","volume":"499","author":"J Chen","year":"2021","unstructured":"Chen J, Qiao YD, Li X, Xu JL, Ye QJ, Jiang N, et al. Intratumoral CD45(+)CD71(+) erythroid cells induce immune tolerance and predict tumor recurrence in hepatocellular carcinoma. Cancer Lett. 2021;499:85\u201398.","journal-title":"Cancer Lett"},{"key":"2477_CR129","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3324\/haematol.2019.243063","volume":"105","author":"S Elahi","year":"2020","unstructured":"Elahi S, Mashhouri S. Immunological consequences of extramedullary erythropoiesis: immunoregulatory functions of CD71(+) erythroid cells. Haematologica. 2020;105:1478\u201383.","journal-title":"Haematologica"},{"key":"2477_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2006649","volume":"16","author":"S Shahbaz","year":"2018","unstructured":"Shahbaz S, Bozorgmehr N, Koleva P, Namdar A, Jovel J, Fava RA, et al. CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-\u03b2. PLoS Biol. 2018;16:e2006649.","journal-title":"PLoS Biol"},{"key":"2477_CR131","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.stemcr.2021.04.001","volume":"16","author":"S Shahbaz","year":"2021","unstructured":"Shahbaz S, Xu L, Osman M, Sligl W, Shields J, Joyce M, et al. Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2. Stem Cell Reports. 2021;16:1165\u201381.","journal-title":"Stem Cell Reports"},{"key":"2477_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02914-4","volume":"4","author":"TM Grzywa","year":"2021","unstructured":"Grzywa TM, Sosnowska A, Rydzynska Z, Lazniewski M, Plewczynski D, Klicka K, et al. Potent but transient immunosuppression of T-cells is a general feature of CD71(+) erythroid cells. Commun Biol. 2021;4:1384.","journal-title":"Commun Biol"},{"key":"2477_CR133","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.it.2019.01.003","volume":"40","author":"S Elahi","year":"2019","unstructured":"Elahi S. Neglected cells: immunomodulatory roles of CD71(+) erythroid cells. Trends Immunol. 2019;40:181\u20135.","journal-title":"Trends Immunol"},{"key":"2477_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705197","volume":"12","author":"S Mashhouri","year":"2021","unstructured":"Mashhouri S, Koleva P, Huynh M, Okoye I, Shahbaz S, Elahi S. Sex matters: physiological abundance of immuno-regulatory CD71+ erythroid cells impair immunity in females. Front Immunol. 2021;12:705197.","journal-title":"Front Immunol"},{"key":"2477_CR135","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ccell.2022.04.018","volume":"40","author":"H Long","year":"2022","unstructured":"Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, et al. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1\/PD-L1 treatment efficacy. Cancer Cell. 2022;40:674-93.e7.","journal-title":"Cancer Cell"},{"key":"2477_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101583","volume":"57","author":"A Bodac","year":"2021","unstructured":"Bodac A, Meylan E. Neutrophil metabolism in the cancer context. Semin Immunol. 2021;57:101583.","journal-title":"Semin Immunol"},{"key":"2477_CR137","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-20-2870","volume":"81","author":"PB Ancey","year":"2021","unstructured":"Ancey PB, Contat C, Boivin G, Sabatino S, Pascual J, Zangger N, et al. Glut1 expression in tumor-associated neutrophils promotes lung cancer growth and resistance to radiotherapy. Cancer Res. 2021;81:2345\u201357.","journal-title":"Cancer Res"},{"key":"2477_CR138","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","volume":"612","author":"R Kim","year":"2022","unstructured":"Kim R, Hashimoto A, Markosyan N, Tyurin VA, Tyurina YY, Kar G, et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022;612:338\u201346.","journal-title":"Nature"},{"key":"2477_CR139","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153643","volume":"132","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhu X, Friesen TJ, Kwak JW, Pisarenko T, Mekvanich S, et al. Annexin A2\/TLR2\/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils. J Clin Invest. 2022;132:e153643.","journal-title":"J Clin Invest"},{"key":"2477_CR140","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ijc.24448","volume":"125","author":"R Rotondo","year":"2009","unstructured":"Rotondo R, Barisione G, Mastracci L, Grossi F, Orengo AM, Costa R, et al. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer. 2009;125:887\u201393.","journal-title":"Int J Cancer"},{"key":"2477_CR141","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1158\/2326-6066.CIR-18-0045","volume":"6","author":"J Yang","year":"2018","unstructured":"Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, et al. Loss of CXCR4 in myeloid cells enhances antitumor immunity and reduces melanoma growth through NK cell and FASL mechanisms. Cancer Immunol Res. 2018;6:1186\u201398.","journal-title":"Cancer Immunol Res"},{"key":"2477_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143369","volume":"14","author":"W Chen","year":"2022","unstructured":"Chen W, Li B, Jia F, Li J, Huang H, Ni C, et al. High PANX1 expression leads to neutrophil recruitment and the formation of a high adenosine immunosuppressive tumor microenvironment in basal-like breast cancer. Cancers (Basel). 2022;14:3369.","journal-title":"Cancers (Basel)"},{"key":"2477_CR143","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612:141\u20137.","journal-title":"Nature"},{"key":"2477_CR144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001946","volume":"9","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Wang P, Sun R, Li J, Hu Z, Xin H, et al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J Immunother Cancer. 2021;9:e001946.","journal-title":"J Immunother Cancer"},{"key":"2477_CR145","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","volume":"150","author":"SL Zhou","year":"2016","unstructured":"Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, et al. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Gastroenterology. 2016;150:1646-58.e17.","journal-title":"Gastroenterology"},{"key":"2477_CR146","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2024.01.013","volume":"42","author":"XY He","year":"2024","unstructured":"He XY, Gao Y, Ng D, Michalopoulou E, George S, Adrover JM, et al. Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell. 2024;42:474-86.e12.","journal-title":"Cancer Cell"},{"key":"2477_CR147","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41590-024-01859-0","volume":"25","author":"BM Fortin","year":"2024","unstructured":"Fortin BM, Pfeiffer SM, Insua-Rodr\u00edguez J, Alshetaiwi H, Moshensky A, Song WA, et al. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat Immunol. 2024;25:1257\u201369.","journal-title":"Nat Immunol"},{"key":"2477_CR148","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24:654\u201369.","journal-title":"Nat Rev Immunol"},{"key":"2477_CR149","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-024-00786-4","volume":"25","author":"P Altea-Manzano","year":"2025","unstructured":"Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A. Metabolic interplays between the tumour and the host shape the tumour macroenvironment. Nat Rev Cancer. 2025;25:274\u201392.","journal-title":"Nat Rev Cancer"},{"key":"2477_CR150","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162:1229\u201341.","journal-title":"Cell"},{"key":"2477_CR151","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.cmet.2022.08.002","volume":"34","author":"D Guo","year":"2022","unstructured":"Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I\u03baB\u03b1. Cell Metab. 2022;34:1312-24.e6.","journal-title":"Cell Metab"},{"key":"2477_CR152","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","volume":"28","author":"W Li","year":"2018","unstructured":"Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metab. 2018;28:87-103.e6.","journal-title":"Cell Metab"},{"key":"2477_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108500","volume":"33","author":"WJ 3rd Quinn","year":"2020","unstructured":"Quinn WJ 3rd, Jiao J, TeSlaa T, Stadanlick J, Wang Z, Wang L, et al. Lactate limits T cell proliferation via the NAD(H) redox state. Cell Rep. 2020;33:108500.","journal-title":"Cell Rep"},{"key":"2477_CR154","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cmet.2022.06.008","volume":"34","author":"I Elia","year":"2022","unstructured":"Elia I, Rowe JH, Johnson S, Joshi S, Notarangelo G, Kurmi K, et al. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8(+) T cells. Cell Metab. 2022;34:1137-50.e6.","journal-title":"Cell Metab"},{"key":"2477_CR155","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41590-023-01738-0","volume":"25","author":"J Ma","year":"2024","unstructured":"Ma J, Tang L, Tan Y, Xiao J, Wei K, Zhang X, et al. Lithium carbonate revitalizes tumor-reactive CD8(+) T cells by shunting lactic acid into mitochondria. Nat Immunol. 2024;25:552\u201361.","journal-title":"Nat Immunol"},{"key":"2477_CR156","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40:201-18.e9.","journal-title":"Cancer Cell"},{"key":"2477_CR157","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591:645\u201351.","journal-title":"Nature"},{"key":"2477_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110986","volume":"39","author":"J Gu","year":"2022","unstructured":"Gu J, Zhou J, Chen Q, Xu X, Gao J, Li X, et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-\u03b2 signaling in regulatory T cells. Cell Rep. 2022;39:110986.","journal-title":"Cell Rep"},{"key":"2477_CR159","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1073\/pnas.1614035114","volume":"114","author":"P Chen","year":"2017","unstructured":"Chen P, Zuo H, Xiong H, Kolar MJ, Chu Q, Saghatelian A, et al. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci U S A. 2017;114:580\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR160","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.cmet.2024.10.019","volume":"36","author":"H Tong","year":"2024","unstructured":"Tong H, Jiang Z, Song L, Tan K, Yin X, He C, et al. Dual impacts of serine\/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Cell Metab. 2024;36:2493-510.e9.","journal-title":"Cell Metab"},{"key":"2477_CR161","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41467-022-29137-3","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun. 2022;13:1511.","journal-title":"Nat Commun"},{"key":"2477_CR162","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1158\/0008-5472.CAN-07-1999","volume":"68","author":"MT Accioly","year":"2008","unstructured":"Accioly MT, Pacheco P, Maya-Monteiro CM, Carrossini N, Robbs BK, Oliveira SS, et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res. 2008;68:1732\u201340.","journal-title":"Cancer Res"},{"key":"2477_CR163","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","volume":"56","author":"F Bayerl","year":"2023","unstructured":"Bayerl F, Meiser P, Donakonda S, Hirschberger A, Lacher SB, Pedde AM, et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity. 2023;56:1341-58.e11.","journal-title":"Immunity"},{"key":"2477_CR164","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay S, van der Veen AG, B\u00f6ttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257\u201370.","journal-title":"Cell"},{"key":"2477_CR165","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1940-6207.CAPR-21-0572","volume":"15","author":"J Wei","year":"2022","unstructured":"Wei J, Zhang J, Wang D, Cen B, Lang JD, DuBois RN. The COX-2-PGE2 pathway promotes tumor evasion in colorectal adenomas. Cancer Prev Res (Phila). 2022;15:285\u201396.","journal-title":"Cancer Prev Res (Phila)"},{"key":"2477_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.00012","volume":"7","author":"S Goto","year":"2020","unstructured":"Goto S, Konnai S, Hirano Y, Kohara J, Okagawa T, Maekawa N, et al. Upregulation of PD-L1 expression by prostaglandin E(2) and the enhancement of IFN-\u03b3 by anti-PD-L1 antibody combined with a COX-2 inhibitor in Mycoplasma bovis infection. Front Vet Sci. 2020;7:12.","journal-title":"Front Vet Sci"},{"key":"2477_CR167","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.4049\/jimmunol.1900342","volume":"203","author":"Y Sajiki","year":"2019","unstructured":"Sajiki Y, Konnai S, Okagawa T, Nishimori A, Maekawa N, Goto S, et al. Prostaglandin E(2)-induced immune exhaustion and enhancement of antiviral effects by anti-PD-L1 antibody combined with COX-2 inhibitor in Bovine Leukemia Virus infection. J Immunol. 2019;203:1313\u201324.","journal-title":"J Immunol"},{"key":"2477_CR168","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu S, Chaudhary O, Rodr\u00edguez-Morales P, Sun X, Chen D, Zappasodi R, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors. Immunity. 2021;54:1561-77.e7.","journal-title":"Immunity"},{"key":"2477_CR169","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma X, Xiao L, Liu L, Ye L, Su P, Bi E, et al. CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33:1001-12.e5.","journal-title":"Cell Metab"},{"key":"2477_CR170","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-023-06299-8","volume":"620","author":"C Guo","year":"2023","unstructured":"Guo C, You Z, Shi H, Sun Y, Du X, Palacios G, et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature. 2023;620:200\u20138.","journal-title":"Nature"},{"key":"2477_CR171","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1038\/s41467-022-34064-4","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Li B, Li S, Lin W, Wang Z, Wang S, et al. Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion. Nat Commun. 2022;13:6308.","journal-title":"Nat Commun"},{"key":"2477_CR172","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","volume":"585","author":"Y Bian","year":"2020","unstructured":"Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585:277\u201382.","journal-title":"Nature"},{"key":"2477_CR173","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.4049\/jimmunol.181.8.5396","volume":"181","author":"W Chen","year":"2008","unstructured":"Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008;181:5396\u2013404.","journal-title":"J Immunol"},{"issue":"1","key":"2477_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37170-z","volume":"14","author":"P Kesarwani","year":"2023","unstructured":"Kesarwani P, Kant S, Zhao Y, Prabhu A, Buelow KL, Miller CR, et al. Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR\/PPAR\u03b3 signaling axis. Nat Commun. 2023;14(1):1459.","journal-title":"Nat Commun"},{"key":"2477_CR175","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-023-06061-0","volume":"617","author":"H Yuan","year":"2023","unstructured":"Yuan H, Wu X, Wu Q, Chatoff A, Megill E, Gao J, et al. Lysine catabolism reprograms tumour immunity through histone crotonylation. Nature. 2023;617:818\u201326.","journal-title":"Nature"},{"key":"2477_CR176","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ccell.2025.03.015","volume":"43","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Zhou Z, Du X, Lin X, Liang ZM, Chen S, et al. Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion. Cancer Cell. 2025;43:1045-60.e7.","journal-title":"Cancer Cell"},{"key":"2477_CR177","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-med-060619-023155","volume":"72","author":"EA Thompson","year":"2021","unstructured":"Thompson EA, Powell JD. Inhibition of the adenosine pathway to potentiate cancer immunotherapy: potential for combinatorial approaches. Annu Rev Med. 2021;72:331\u201348.","journal-title":"Annu Rev Med"},{"key":"2477_CR178","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108130","volume":"40","author":"O Kepp","year":"2021","unstructured":"Kepp O, Bezu L, Yamazaki T, Di Virgilio F, Smyth MJ, Kroemer G, et al. ATP and cancer immunosurveillance. EMBO J. 2021;40:e108130.","journal-title":"EMBO J"},{"key":"2477_CR179","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17:611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"2477_CR180","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s43018-024-00771-8","volume":"5","author":"T Scolaro","year":"2024","unstructured":"Scolaro T, Manco M, Pecqueux M, Amorim R, Trotta R, Van Acker HH, et al. Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance. Nat Cancer. 2024;5:1206\u201326.","journal-title":"Nat Cancer"},{"key":"2477_CR181","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41556-025-01627-8","volume":"27","author":"Y Duan","year":"2025","unstructured":"Duan Y, Hu Z, Han P, Lei B, Wang S, Wang Z, et al. ADSL-generated fumarate binds and inhibits STING to promote tumour immune evasion. Nat Cell Biol. 2025;27:668\u201382.","journal-title":"Nat Cell Biol"},{"key":"2477_CR182","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12943-025-02407-6","volume":"24","author":"Y Lv","year":"2025","unstructured":"Lv Y, Li Z, Liu S, Zhou Z, Song J, Ba Y, et al. Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy. Mol Cancer. 2025;24:210.","journal-title":"Mol Cancer"},{"key":"2477_CR183","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/lifemeta\/loac038","volume":"1","author":"XY Ke","year":"2022","unstructured":"Ke XY, Zou M, Xu C. Lipid metabolism in tumor-infiltrating T cells: mechanisms and applications. Life Metab. 2022;1:211\u201323.","journal-title":"Life Metab"},{"key":"2477_CR184","doi-asserted-by":"publisher","DOI":"10.1093\/lifemeta\/load002","volume":"2","author":"M Peng","year":"2023","unstructured":"Peng M, Li MO. Metabolism along the life journey of T cells. Life Metab. 2023;2:load002.","journal-title":"Life Metab"},{"key":"2477_CR185","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355\u201377.","journal-title":"Cell Metab"},{"key":"2477_CR186","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24:657\u201371.","journal-title":"Cell Metab"},{"key":"2477_CR187","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk7399","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang F, Peng D, Zhang D, Liu L, Wei J, et al. Activation and antitumor immunity of CD8(+) T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid. Sci Transl Med. 2024;16:eadk7399.","journal-title":"Sci Transl Med"},{"key":"2477_CR188","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1172\/JCI123027","volume":"129","author":"N Liu","year":"2019","unstructured":"Liu N, Luo J, Kuang D, Xu S, Duan Y, Xia Y, et al. Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2\u03b1-mediated tumor progression. J Clin Invest. 2019;129:631\u201346.","journal-title":"J Clin Invest"},{"key":"2477_CR189","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1158\/0008-5472.CAN-23-2521","volume":"84","author":"G Shu","year":"2024","unstructured":"Shu G, Chen M, Liao W, Fu L, Lin M, Gui C, et al. PABPC1L induces IDO1 to promote tryptophan metabolism and immune suppression in renal cell carcinoma. Cancer Res. 2024;84:1659\u201379.","journal-title":"Cancer Res"},{"key":"2477_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-kynurenine. Nat Commun. 2020;11:4011.","journal-title":"Nat Commun"},{"key":"2477_CR191","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1074\/jbc.M116.766238","volume":"292","author":"LA Van de Velde","year":"2017","unstructured":"Van de Velde LA, Subramanian C, Smith AM, Barron L, Qualls JE, Neale G, et al. T cells encountering myeloid cells programmed for amino acid-dependent immunosuppression use Rictor\/mTORC2 protein for proliferative checkpoint decisions. J Biol Chem. 2017;292:15\u201330.","journal-title":"J Biol Chem"},{"key":"2477_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102111","volume":"94","author":"P St\u00fcve","year":"2025","unstructured":"St\u00fcve P, Godoy GJ, Ferreyra FN, Hellriegel F, Boukhallouk F, Kao YS, et al. ACC1 is a dual metabolic-epigenetic regulator of Treg stability and immune tolerance. Mol Metab. 2025;94:102111.","journal-title":"Mol Metab"},{"key":"2477_CR193","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131073","volume":"10","author":"VR Moulton","year":"2015","unstructured":"Moulton VR, Gillooly AR, Perl MA, Markopoulou A, Tsokos GC. Serine arginine-rich splicing factor 1 (SRSF1) contributes to the transcriptional activation of CD3\u03b6 in human T cells. PLoS ONE. 2015;10:e0131073.","journal-title":"PLoS ONE"},{"key":"2477_CR194","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-025-01038-9","volume":"47","author":"E Karadima","year":"2025","unstructured":"Karadima E, Chavakis T, Alexaki VI. Arginine metabolism in myeloid cells in health and disease. Semin Immunopathol. 2025;47:11.","journal-title":"Semin Immunopathol"},{"key":"2477_CR195","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang H, Franco F, Tsui YC, Xie X, Trefny MP, Zappasodi R, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21:298\u2013308.","journal-title":"Nat Immunol"},{"key":"2477_CR196","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002840","author":"R Qin","year":"2021","unstructured":"Qin R, Zhao C, Wang CJ, Xu W, Zhao JY, Lin Y, et al. Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002840.","journal-title":"J Immunother Cancer"},{"key":"2477_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"SM Steggerda","year":"2017","unstructured":"Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017;5:101.","journal-title":"J Immunother Cancer"},{"key":"2477_CR198","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013\u201321.","journal-title":"Science"},{"key":"2477_CR199","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","volume":"41","author":"D Hanahan","year":"2023","unstructured":"Hanahan D, Monje M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell. 2023;41:573\u201380.","journal-title":"Cancer Cell"},{"key":"2477_CR200","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41573-024-01017-z","volume":"23","author":"D Yaniv","year":"2024","unstructured":"Yaniv D, Mattson B, Talbot S, Gleber-Netto FO, Amit M. Targeting the peripheral neural-tumour microenvironment for cancer therapy. Nat Rev Drug Discov. 2024;23:780\u201396.","journal-title":"Nat Rev Drug Discov"},{"key":"2477_CR201","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00262-014-1617-9","volume":"63","author":"JW Eng","year":"2014","unstructured":"Eng JW, Kokolus KM, Reed CB, Hylander BL, Ma WW, Repasky EA. A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol Immunother. 2014;63:1115\u201328.","journal-title":"Cancer Immunol Immunother"},{"key":"2477_CR202","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41586-023-06568-6","volume":"622","author":"AM Globig","year":"2023","unstructured":"Globig AM, Zhao S, Roginsky J, Maltez VI, Guiza J, Avina-Ochoa N, et al. The \u03b2(1)-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature. 2023;622:383\u201392.","journal-title":"Nature"},{"key":"2477_CR203","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1158\/0008-5472.CAN-17-0546","volume":"77","author":"MJ Bucsek","year":"2017","unstructured":"Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, et al. \u03b2-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. Cancer Res. 2017;77:5639\u201351.","journal-title":"Cancer Res"},{"key":"2477_CR204","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41586-020-1996-3","volume":"578","author":"M Amit","year":"2020","unstructured":"Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, et al. Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 2020;578:449\u201354.","journal-title":"Nature"},{"key":"2477_CR205","doi-asserted-by":"publisher","first-page":"1236361","DOI":"10.1126\/science.1236361","volume":"341","author":"C Magnon","year":"2013","unstructured":"Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.","journal-title":"Science"},{"key":"2477_CR206","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2022.01.017","volume":"165","author":"OJ Kennedy","year":"2022","unstructured":"Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, et al. Prognostic and predictive value of \u03b2-blockers in the EORTC 1325\/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2022;165:97\u2013112.","journal-title":"Eur J Cancer"},{"key":"2477_CR207","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1016\/j.cllc.2020.07.016","volume":"22","author":"MS Oh","year":"2021","unstructured":"Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, et al. The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Clin Lung Cancer. 2021;22:e57\u201362.","journal-title":"Clin Lung Cancer"},{"key":"2477_CR208","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1016\/j.ajpath.2014.08.009","volume":"184","author":"J Pundavela","year":"2014","unstructured":"Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, et al. ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer. Am J Pathol. 2014;184:3156\u201362.","journal-title":"Am J Pathol"},{"key":"2477_CR209","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-022-05374-w","volume":"611","author":"M Balood","year":"2022","unstructured":"Balood M, Ahmadi M, Eichwald T, Ahmadi A, Majdoubi A, Roversi K, et al. Nociceptor neurons affect cancer immunosurveillance. Nature. 2022;611:405\u201312.","journal-title":"Nature"},{"key":"2477_CR210","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202200019","volume":"6","author":"LA McIlvried","year":"2022","unstructured":"McIlvried LA, Atherton MA, Horan NL, Goch TN, Scheff NN. Sensory neurotransmitter calcitonin gene-related peptide modulates tumor growth and lymphocyte infiltration in oral squamous cell carcinoma. Adv Biol. 2022;6:e2200019.","journal-title":"Adv Biol"},{"key":"2477_CR211","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cell.2020.11.028","volume":"184","author":"S Huang","year":"2021","unstructured":"Huang S, Ziegler CGK, Austin J, Mannoun N, Vukovic M, Ordovas-Montanes J, et al. Lymph nodes are innervated by a unique population of sensory neurons with immunomodulatory potential. Cell. 2021;184:441-59.e25.","journal-title":"Cell"},{"key":"2477_CR212","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1097\/QAD.0000000000000638","volume":"29","author":"P Tebas","year":"2015","unstructured":"Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, et al. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS. 2015;29:931\u20139.","journal-title":"AIDS"},{"key":"2477_CR213","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3390\/cancers2020611","volume":"2","author":"M Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz M, Rosso M, Gonz\u00e1lez-Ortega A, Cove\u00f1as R. The NK-1 receptor antagonist L-732,138 induces apoptosis and counteracts substance p-related mitogenesis in human melanoma cell lines. Cancers (Basel). 2010;2:611\u201323.","journal-title":"Cancers (Basel)"},{"key":"2477_CR214","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/0008-5472.CAN-12-4573","volume":"73","author":"S Garcia-Recio","year":"2013","unstructured":"Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, et al. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 2013;73:6424\u201334.","journal-title":"Cancer Res"},{"key":"2477_CR215","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/sj.bjc.6690039","volume":"79","author":"C Palma","year":"1999","unstructured":"Palma C, Nardelli F, Manzini S, Maggi CA. Substance p activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer. 1999;79:236\u201343.","journal-title":"Br J Cancer"},{"key":"2477_CR216","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00262-020-02574-z","volume":"69","author":"E Nizam","year":"2020","unstructured":"Nizam E, K\u00f6ksoy S, Erin N. NK1r antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences. Cancer Immunol Immunother. 2020;69:1639\u201350.","journal-title":"Cancer Immunol Immunother"},{"key":"2477_CR217","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1158\/0008-5472.CAN-16-1701","volume":"78","author":"JK Allen","year":"2018","unstructured":"Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, et al. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Res. 2018;78:3233\u201342.","journal-title":"Cancer Res"},{"key":"2477_CR218","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature12416","volume":"501","author":"WJ Zhou","year":"2013","unstructured":"Zhou WJ, Geng ZH, Spence JR, Geng JG. Induction of intestinal stem cells by R-spondin 1 and Slit2 augments chemoradioprotection. Nature. 2013;501:107\u201311.","journal-title":"Nature"},{"key":"2477_CR219","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00408","volume":"9","author":"Z Gugala","year":"2018","unstructured":"Gugala Z, Olmsted-Davis EA, Xiong Y, Davis EL, Davis AR. Trauma-induced heterotopic ossification regulates the blood-nerve barrier. Front Neurol. 2018;9:408.","journal-title":"Front Neurol"},{"key":"2477_CR220","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.01038","volume":"12","author":"M Richner","year":"2018","unstructured":"Richner M, Ferreira N, Dudele A, Jensen TS, Vaegter CB, Gon\u00e7alves NP. Functional and structural changes of the blood-nerve-barrier in diabetic neuropathy. Front Neurosci. 2018;12:1038.","journal-title":"Front Neurosci"},{"key":"2477_CR221","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01199-6","author":"A Leunig","year":"2025","unstructured":"Leunig A, Gianeselli M, Russo SJ, Swirski FK. Connection and communication between the nervous and immune systems. Nat Rev Immunol. 2025. https:\/\/doi.org\/10.1038\/s41577-025-01199-6.","journal-title":"Nat Rev Immunol"},{"key":"2477_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09370-8","author":"EN Baruch","year":"2025","unstructured":"Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, et al. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-025-09370-8.","journal-title":"Nature"},{"key":"2477_CR223","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-022-05605-0","volume":"614","author":"C Wang","year":"2023","unstructured":"Wang C, Barnoud C, Cenerenti M, Sun M, Caffa I, Kizil B, et al. Dendritic cells direct circadian anti-tumour immune responses. Nature. 2023;614:136\u201343.","journal-title":"Nature"},{"key":"2477_CR224","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","volume":"22","author":"DC Qian","year":"2021","unstructured":"Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22:1777\u201386.","journal-title":"Lancet Oncol"},{"key":"2477_CR225","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040896","author":"A Karabou\u00e9","year":"2022","unstructured":"Karabou\u00e9 A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, et al. Time-dependent efficacy of checkpoint inhibitor Nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14040896.","journal-title":"Cancers (Basel)"},{"key":"2477_CR226","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","volume":"187","author":"C Wang","year":"2024","unstructured":"Wang C, Zeng Q, G\u00fcl ZM, Wang S, Pick R, Cheng P, et al. Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy. Cell. 2024;187:2690-702.e17.","journal-title":"Cell"},{"issue":"4","key":"2477_CR227","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s43018-024-00759-4","volume":"5","author":"Y Wang","year":"2024","unstructured":"Wang Y, Narasimamurthy R, Qu M, Shi N, Guo H, Xue Y, et al. Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis. Nat Cancer. 2024;5(4):546\u201356.","journal-title":"Nat Cancer"},{"key":"2477_CR228","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41580-024-00802-3","volume":"26","author":"T Mortimer","year":"2025","unstructured":"Mortimer T, Smith JG, Mu\u00f1oz-C\u00e1noves P, Benitah SA. Circadian clock communication during homeostasis and ageing. Nat Rev Mol Cell Biol. 2025;26:314\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2477_CR229","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16890-6","volume":"11","author":"E Hadadi","year":"2020","unstructured":"Hadadi E, Taylor W, Li XM, Aslan Y, Villote M, Rivi\u00e8re J, et al. Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat Commun. 2020;11:3193.","journal-title":"Nat Commun"},{"key":"2477_CR230","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-immunol-090122-050842","volume":"42","author":"R Pick","year":"2024","unstructured":"Pick R, Wang C, Zeng Q, G\u00fcl ZM, Scheiermann C. Circadian rhythms in anticancer immunity: mechanisms and treatment opportunities. Annu Rev Immunol. 2024;42:83\u2013102.","journal-title":"Annu Rev Immunol"},{"key":"2477_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217542","volume":"614","author":"YH Li","year":"2025","unstructured":"Li YH, Huang XJ, Zhao XY. Translational study of the regulatory mechanism by which immune synapses enhance immune cell function. Cancer Lett. 2025;614:217542.","journal-title":"Cancer Lett"},{"key":"2477_CR232","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nri1245","volume":"3","author":"JB Huppa","year":"2003","unstructured":"Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol. 2003;3:973\u201383.","journal-title":"Nat Rev Immunol"},{"key":"2477_CR233","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101975","volume":"6","author":"X Zhou","year":"2025","unstructured":"Zhou X, Xu T, Li C, He Y, Hu Y, Gong H, et al. Potentiating anti-tumor immunity by re-engaging immune synapse molecules. Cell Rep Med. 2025;6:101975.","journal-title":"Cell Rep Med"},{"key":"2477_CR234","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41590-023-01462-9","volume":"24","author":"X Zheng","year":"2023","unstructured":"Zheng X, Hou Z, Qian Y, Zhang Y, Cui Q, Wang X, et al. Tumors evade immune cytotoxicity by altering the surface topology of NK cells. Nat Immunol. 2023;24:802\u201313.","journal-title":"Nat Immunol"},{"key":"2477_CR235","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","volume":"6","author":"WK Chan","year":"2018","unstructured":"Chan WK, Kang S, Youssef Y, Glankler EN, Barrett ER, Carter AM, et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunol Res. 2018;6:776\u201387.","journal-title":"Cancer Immunol Res"},{"key":"2477_CR236","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4049\/jimmunol.2100487","volume":"208","author":"QN Shang","year":"2022","unstructured":"Shang QN, Yu XX, Xu ZL, Cao XH, Liu XF, Zhao XS, et al. Functional competence of NK cells via the KIR\/MHC class I interaction correlates with DNAM-1 expression. J Immunol. 2022;208:492\u2013500.","journal-title":"J Immunol"},{"key":"2477_CR237","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clim.2019.05.010","volume":"205","author":"XX Yu","year":"2019","unstructured":"Yu XX, Cao XH, Yan H, Luo XY, Zhao XS, Sun YQ, et al. Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation. Clin Immunol. 2019;205:49\u201356.","journal-title":"Clin Immunol"},{"key":"2477_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216909","volume":"592","author":"X Shi","year":"2024","unstructured":"Shi X, Chen W, Yin Y, Cao H, Wang X, Jiang W, et al. RAC1(high) NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis. Cancer Lett. 2024;592:216909.","journal-title":"Cancer Lett"},{"key":"2477_CR239","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf9792","author":"Y Wei","year":"2021","unstructured":"Wei Y, Ren X, Galbo PM Jr., Moerdler S, Wang H, Sica RA, et al. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021. https:\/\/doi.org\/10.1126\/sciimmunol.abf9792.","journal-title":"Sci Immunol"},{"key":"2477_CR240","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.814334","volume":"13","author":"W Zuo","year":"2022","unstructured":"Zuo W, Yu XX, Liu XF, Chang YJ, Wang Y, Zhang XH, et al. The Interaction of HLA-C1\/KIR2DL2\/L3 Promoted KIR2DL2\/L3 Single-Positive\/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Front Immunol. 2022;13:814334.","journal-title":"Front Immunol"},{"key":"2477_CR241","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163620","volume":"132","author":"X Ren","year":"2022","unstructured":"Ren X, Peng M, Xing P, Wei Y, Galbo PM Jr., Corrigan D, et al. Blockade of the immunosuppressive KIR2DL5\/PVR pathway elicits potent human NK cell-mediated antitumor immunity. J Clin Invest. 2022;132:e163620.","journal-title":"J Clin Invest"},{"key":"2477_CR242","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ceb.2021.02.008","volume":"71","author":"T Douanne","year":"2021","unstructured":"Douanne T, Griffiths GM. Cytoskeletal control of the secretory immune synapse. Curr Opin Cell Biol. 2021;71:87\u201394.","journal-title":"Curr Opin Cell Biol"},{"key":"2477_CR243","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.abp8933","volume":"380","author":"JC Stinchcombe","year":"2023","unstructured":"Stinchcombe JC, Asano Y, Kaufman CJG, B\u00f6hlig K, Peddie CJ, Collinson LM, et al. Ectocytosis renders T cell receptor signaling self-limiting at the immune synapse. Science. 2023;380:818\u201323.","journal-title":"Science"},{"key":"2477_CR244","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.trecan.2025.01.012","volume":"11","author":"L Cheng","year":"2025","unstructured":"Cheng L, Wang Y, Zhang Y. Dying to survive: harnessing inflammatory cell death for better immunotherapy. Trends Cancer. 2025;11:376\u2013402.","journal-title":"Trends Cancer"},{"key":"2477_CR245","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00769-0","volume":"19","author":"Y Duan","year":"2021","unstructured":"Duan Y, Tian X, Liu Q, Jin J, Shi J, Hou Y. Role of autophagy on cancer immune escape. Cell Commun Signal. 2021;19:91.","journal-title":"Cell Commun Signal"},{"key":"2477_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216661","volume":"585","author":"M Cordani","year":"2024","unstructured":"Cordani M, Strippoli R, Trionfetti F, Barzegar Behrooz A, Rumio C, Velasco G, et al. Immune checkpoints between epithelial-mesenchymal transition and autophagy: a conflicting triangle. Cancer Lett. 2024;585:216661.","journal-title":"Cancer Lett"},{"key":"2477_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37376","volume":"10","author":"M Hashemi","year":"2024","unstructured":"Hashemi M, Mohandesi Khosroshahi E, Tanha M, Khoushab S, Bizhanpour A, Azizi F, et al. Targeting autophagy can synergize the efficacy of immune checkpoint inhibitors against therapeutic resistance: new promising strategy to reinvigorate cancer therapy. Heliyon. 2024;10:e37376.","journal-title":"Heliyon"},{"key":"2477_CR248","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41568-021-00344-2","volume":"21","author":"H Xia","year":"2021","unstructured":"Xia H, Green DR, Zou W. Autophagy in tumour immunity and therapy. Nat Rev Cancer. 2021;21:281\u201397.","journal-title":"Nat Rev Cancer"},{"key":"2477_CR249","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2326-6066.CIR-23-0622","volume":"12","author":"TT Liao","year":"2024","unstructured":"Liao TT, Chen YH, Li ZY, Hsiao AC, Huang YL, Hao RX, et al. Hypoxia-induced long noncoding RNA HIF1A-AS2 regulates stability of MHC class I protein in head and neck cancer. Cancer Immunol Res. 2024;12:1468\u201384.","journal-title":"Cancer Immunol Res"},{"key":"2477_CR250","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 2019;15:42\u201350.","journal-title":"Nat Chem Biol"},{"key":"2477_CR251","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1158\/0008-5472.CAN-23-3971","volume":"84","author":"D Liu","year":"2024","unstructured":"Liu D, Li M, Zhao Z, Zhou L, Zhi F, Guo Z, et al. Targeting the TRIM14\/USP14 axis enhances immunotherapy efficacy by inducing autophagic degradation of PD-L1. Cancer Res. 2024;84:2806\u201319.","journal-title":"Cancer Res"},{"key":"2477_CR252","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02277-y","volume":"24","author":"H Wang","year":"2025","unstructured":"Wang H, Sun P, Yuan X, Xu Z, Jiang X, Xiao M, et al. Autophagy in tumor immune escape and immunotherapy. Mol Cancer. 2025;24:85.","journal-title":"Mol Cancer"},{"key":"2477_CR253","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1038\/s41388-025-03488-9","volume":"44","author":"M Zhao","year":"2025","unstructured":"Zhao M, Nie J, Ye A, Liu C, Li X, Yang Z, et al. Impaired autophagy by cepharanthine induces immunogenic cell death and enhances anti-PD-1 response in MSS-type colorectal cancer. Oncogene. 2025;44:3171\u201382.","journal-title":"Oncogene"},{"key":"2477_CR254","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03225-9","volume":"9","author":"D Chen","year":"2018","unstructured":"Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9:873.","journal-title":"Nat Commun"},{"key":"2477_CR255","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s43018-021-00208-6","volume":"2","author":"J Deng","year":"2021","unstructured":"Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. Nat Cancer. 2021;2:503\u201314.","journal-title":"Nat Cancer"},{"key":"2477_CR256","doi-asserted-by":"crossref","unstructured":"N A L, Eljack S, and Saber-Ayad M M. Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1\/PD-L1 Therapy for Colorectal Cancer Treatment. Cells. 2025;14:745.","DOI":"10.3390\/cells14100745"},{"key":"2477_CR257","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1084\/jem.20190041","volume":"216","author":"P Ou","year":"2019","unstructured":"Ou P, Wen L, Liu X, Huang J, Huang X, Su C, et al. Thioesterase PPT1 balances viral resistance and efficient T cell crosspriming in dendritic cells. J Exp Med. 2019;216:2091\u2013112.","journal-title":"J Exp Med"},{"key":"2477_CR258","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s43018-021-00237-1","volume":"2","author":"Y Qiao","year":"2021","unstructured":"Qiao Y, Choi JE, Tien JC, Simko SA, Rajendiran T, Vo JN, et al. Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nat Cancer. 2021;2:978\u201393.","journal-title":"Nat Cancer"},{"key":"2477_CR259","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/cr.2015.56","volume":"25","author":"GB Koo","year":"2015","unstructured":"Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015;25:707\u201325.","journal-title":"Cell Res"},{"key":"2477_CR260","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1158\/1078-0432.CCR-18-3683","volume":"27","author":"Y Tan","year":"2021","unstructured":"Tan Y, Sementino E, Cheung M, Peri S, Menges CW, Kukuyan AM, et al. Somatic epigenetic silencing of RIPK3 inactivates necroptosis and contributes to chemoresistance in malignant mesothelioma. Clin Cancer Res. 2021;27:1200\u201313.","journal-title":"Clin Cancer Res"},{"key":"2477_CR261","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw2004","author":"AG Snyder","year":"2019","unstructured":"Snyder AG, Hubbard NW, Messmer MN, Kofman SB, Hagan CE, Orozco SL, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol. 2019. https:\/\/doi.org\/10.1126\/sciimmunol.aaw2004.","journal-title":"Sci Immunol"},{"key":"2477_CR262","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.860546","volume":"13","author":"Y Xia","year":"2022","unstructured":"Xia Y, Jin Y, Cui D, Wu X, Song C, Jin W, et al. Antitumor effect of simvastatin in combination with DNA methyltransferase inhibitor on gastric cancer via GSDME-mediated pyroptosis. Front Pharmacol. 2022;13:860546.","journal-title":"Front Pharmacol"},{"key":"2477_CR263","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1016\/j.apsb.2022.11.002","volume":"12","author":"Q Niu","year":"2022","unstructured":"Niu Q, Liu Y, Zheng Y, Tang Z, Qian Y, Qi R, et al. Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics. Acta Pharm Sin B. 2022;12:4458\u201371.","journal-title":"Acta Pharm Sin B"},{"key":"2477_CR264","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57\u201362.","journal-title":"Nature"},{"key":"2477_CR265","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/0008-5472.CAN-18-3037","volume":"79","author":"T Liu","year":"2019","unstructured":"Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79:1913\u201324.","journal-title":"Cancer Res"},{"key":"2477_CR266","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110710","volume":"108","author":"C Cai","year":"2023","unstructured":"Cai C, Zhu Y, Mu J, Liu S, Yang Z, Wu Z, et al. DNA methylation of RUNX3 promotes the progression of gallbladder cancer through repressing SLC7A11-mediated ferroptosis. Cell Signal. 2023;108:110710.","journal-title":"Cell Signal"},{"key":"2477_CR267","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688\u201392.","journal-title":"Nature"},{"key":"2477_CR268","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41586-025-08950-y","volume":"642","author":"JH Hurley","year":"2025","unstructured":"Hurley JH, Coyne AN, Mi\u0105czy\u0144ska M, Stenmark H. The expanding repertoire of ESCRT functions in cell biology and disease. Nature. 2025;642:877\u201388.","journal-title":"Nature"},{"key":"2477_CR269","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205590119","volume":"119","author":"S Shukla","year":"2022","unstructured":"Shukla S, Larsen KP, Ou C, Rose K, Hurley JH. In vitro reconstitution of calcium-dependent recruitment of the human ESCRT machinery in lysosomal membrane repair. Proc Natl Acad Sci U S A. 2022;119:e2205590119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR270","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247136","volume":"343","author":"AJ Jimenez","year":"2014","unstructured":"Jimenez AJ, Maiuri P, Lafaurie-Janvore J, Divoux S, Piel M, Perez F. Escrt machinery is required for plasma membrane repair. Science. 2014;343:1247136.","journal-title":"Science"},{"issue":"91","key":"2477_CR271","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq6541","volume":"9","author":"C Stefani","year":"2024","unstructured":"Stefani C, Bruchez AM, Rosasco MG, Yoshida AE, Fasano KJ, Levan PF, et al. Litaf protects against pore-forming protein-induced cell death by promoting membrane repair. Sci Immunol. 2024;9(91):eabq6541.","journal-title":"Sci Immunol"},{"key":"2477_CR272","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41577-021-00602-2","volume":"21","author":"F Shao","year":"2021","unstructured":"Shao F. Gasdermins: making pores for pyroptosis. Nat Rev Immunol. 2021;21:620\u20131.","journal-title":"Nat Rev Immunol"},{"key":"2477_CR273","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.aar7607","volume":"362","author":"S R\u00fchl","year":"2018","unstructured":"R\u00fchl S, Shkarina K, Demarco B, Heilig R, Santos JC, Broz P. Escrt-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science. 2018;362:956\u201360.","journal-title":"Science"},{"key":"2477_CR274","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022110780","volume":"42","author":"Y Liao","year":"2023","unstructured":"Liao Y, Chen X, Miller-Little W, Wang H, Willard B, Bulek K, et al. The Ras GTPase-activating-like protein IQGAP1 bridges Gasdermin D to the ESCRT system to promote IL-1\u03b2 release via exosomes. EMBO J. 2023;42:e110780.","journal-title":"EMBO J"},{"key":"2477_CR275","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41556-021-00706-w","volume":"23","author":"A Claude-Taupin","year":"2021","unstructured":"Claude-Taupin A, Jia J, Bhujabal Z, Garfa-Traor\u00e9 M, Kumar S, da Silva GPD, et al. ATG9A protects the plasma membrane from programmed and incidental permeabilization. Nat Cell Biol. 2021;23:846\u201358.","journal-title":"Nat Cell Biol"},{"key":"2477_CR276","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s43587-024-00575-6","volume":"4","author":"K Suda","year":"2024","unstructured":"Suda K, Moriyama Y, Razali N, Chiu Y, Masukagami Y, Nishimura K, et al. Plasma membrane damage limits replicative lifespan in yeast and induces premature senescence in human fibroblasts. Nat Aging. 2024;4:319\u201335.","journal-title":"Nat Aging"},{"key":"2477_CR277","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34036-8","volume":"13","author":"Z Li","year":"2022","unstructured":"Li Z, Mo F, Wang Y, Li W, Chen Y, Liu J, et al. Enhancing gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. Nat Commun. 2022;13:6321.","journal-title":"Nat Commun"},{"key":"2477_CR278","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1126\/science.abl3855","volume":"376","author":"AT Ritter","year":"2022","unstructured":"Ritter AT, Shtengel G, Xu CS, Weigel A, Hoffman DP, Freeman M, et al. Escrt-mediated membrane repair protects tumor-derived cells against T cell attack. Science. 2022;376:377\u201382.","journal-title":"Science"},{"key":"2477_CR279","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/s41418-020-00691-x","volume":"28","author":"L Pedrera","year":"2021","unstructured":"Pedrera L, Espiritu RA, Ros U, Weber J, Schmitt A, Stroh J, et al. Ferroptotic pores induce Ca(2+) fluxes and ESCRT-III activation to modulate cell death kinetics. Cell Death Differ. 2021;28:1644\u201357.","journal-title":"Cell Death Differ"},{"key":"2477_CR280","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2019.11.110","volume":"522","author":"E Dai","year":"2020","unstructured":"Dai E, Meng L, Kang R, Wang X, Tang D. Escrt-III-dependent membrane repair blocks ferroptosis. Biochem Biophys Res Commun. 2020;522:415\u201321.","journal-title":"Biochem Biophys Res Commun"},{"key":"2477_CR281","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.immuni.2017.06.001","volume":"47","author":"S Yoon","year":"2017","unstructured":"Yoon S, Kovalenko A, Bogdanov K, Wallach D. MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. Immunity. 2017;47:51-65.e7.","journal-title":"Immunity"},{"key":"2477_CR282","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31713-6","volume":"13","author":"L Guan","year":"2022","unstructured":"Guan L, Wu B, Li T, Beer LA, Sharma G, Li M, et al. HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8(+) T-cell infiltration into tumors. Nat Commun. 2022;13:4078.","journal-title":"Nat Commun"},{"key":"2477_CR283","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29469-0","volume":"13","author":"D Bernareggi","year":"2022","unstructured":"Bernareggi D, Xie Q, Prager BC, Yun J, Cruz LS, Pham TV, et al. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity. Nat Commun. 2022;13:1899.","journal-title":"Nat Commun"},{"key":"2477_CR284","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2016.04.076","volume":"15","author":"S Manteghi","year":"2016","unstructured":"Manteghi S, Gingras MC, Kharitidi D, Galarneau L, Marques M, Yan M, et al. Haploinsufficiency of the ESCRT component HD-PTP predisposes to cancer. Cell Rep. 2016;15:1893\u2013900.","journal-title":"Cell Rep"},{"key":"2477_CR285","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910812","volume":"12","author":"E Szyma\u0144ska","year":"2020","unstructured":"Szyma\u0144ska E, Nowak P, Kolmus K, Cybulska M, Goryca K, Derezi\u0144ska-Wo\u0142ek E, et al. Synthetic lethality between VPS4A and VPS4B triggers an inflammatory response in colorectal cancer. EMBO Mol Med. 2020;12:e10812.","journal-title":"EMBO Mol Med"},{"key":"2477_CR286","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108493","volume":"33","author":"JE Neggers","year":"2020","unstructured":"Neggers JE, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Yang A, et al. Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers harboring loss of chromosome 18q or 16q. Cell Rep. 2020;33:108493.","journal-title":"Cell Rep"},{"key":"2477_CR287","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/15548627.2023.2267958","volume":"20","author":"SM Migliano","year":"2024","unstructured":"Migliano SM, Schultz SW, Wenzel EM, Tak\u00e1ts S, Liu D, M\u00f8rk S, et al. Removal of hypersignaling endosomes by simaphagy. Autophagy. 2024;20:769\u201391.","journal-title":"Autophagy"},{"key":"2477_CR288","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.250951","author":"K Kolmus","year":"2021","unstructured":"Kolmus K, Erdenebat P, Szyma\u0144ska E, Stewig B, Goryca K, Derezi\u0144ska-Wo\u0142ek E, et al. Concurrent depletion of Vps37 proteins evokes ESCRT-I destabilization and profound cellular stress responses. J Cell Sci. 2021. https:\/\/doi.org\/10.1242\/jcs.250951.","journal-title":"J Cell Sci"},{"key":"2477_CR289","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1083\/jcb.201902170","volume":"218","author":"Y Takahashi","year":"2019","unstructured":"Takahashi Y, Liang X, Hattori T, Tang Z, He H, Chen H, et al. VPS37A directs ESCRT recruitment for phagophore closure. J Cell Biol. 2019;218:3336\u201354.","journal-title":"J Cell Biol"},{"key":"2477_CR290","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00262-013-1426-6","volume":"62","author":"X Wang","year":"2013","unstructured":"Wang X, Lu XL, Zhao HY, Zhang FC, Jiang XB. A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice. Cancer Immunol Immunother. 2013;62:1261\u201372.","journal-title":"Cancer Immunol Immunother"},{"key":"2477_CR291","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay1357","volume":"5","author":"JM Williford","year":"2019","unstructured":"Williford JM, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell TM, et al. Recruitment of CD103(+) dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv. 2019;5:eaay1357.","journal-title":"Sci Adv"},{"key":"2477_CR292","first-page":"63","volume":"16","author":"EC Eckert","year":"2020","unstructured":"Eckert EC, Nace RA, Tonne JM, Evgin L, Vile RG, Russell SJ. Generation of a tumor-specific chemokine gradient using oncolytic vesicular stomatitis virus encoding CXCL9. Mol Ther. 2020;16:63\u201374.","journal-title":"Mol Ther"},{"key":"2477_CR293","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1091554","volume":"5","author":"Z Liu","year":"2016","unstructured":"Liu Z, Ravindranathan R, Li J, Kalinski P, Guo ZS, Bartlett DL. CXCL11-armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology. 2016;5:e1091554.","journal-title":"Oncoimmunology"},{"key":"2477_CR294","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346\u201351.","journal-title":"Nat Biotechnol"},{"key":"2477_CR295","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","volume":"21","author":"K Kurose","year":"2015","unstructured":"Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, et al. Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res. 2015;21:4327\u201336.","journal-title":"Clin Cancer Res"},{"key":"2477_CR296","first-page":"827","volume":"83","author":"T Saito","year":"2021","unstructured":"Saito T, Kurose K, Kojima T, Funakoshi T, Sato E, Nishikawa H, et al. Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors. Nagoya J Med Sci. 2021;83:827\u201340.","journal-title":"Nagoya J Med Sci"},{"key":"2477_CR297","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","volume":"31","author":"KJ Pienta","year":"2013","unstructured":"Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs. 2013;31:760\u20138.","journal-title":"Invest New Drugs"},{"issue":"21","key":"2477_CR298","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94296","volume":"2","author":"C Dominguez","year":"2017","unstructured":"Dominguez C, McCampbell KK, David JM, Palena C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight. 2017;2(21):e94296.","journal-title":"JCI Insight"},{"key":"2477_CR299","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0706-x","volume":"7","author":"M Bilusic","year":"2019","unstructured":"Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019;7:240.","journal-title":"J Immunother Cancer"},{"key":"2477_CR300","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10:4016.","journal-title":"Nat Commun"},{"key":"2477_CR301","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","volume":"5","author":"S Lesch","year":"2021","unstructured":"Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat Biomed Eng. 2021;5:1246\u201360.","journal-title":"Nat Biomed Eng"},{"key":"2477_CR302","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi5781","volume":"7","author":"BL Cadilha","year":"2021","unstructured":"Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 2021;7:eabi5781.","journal-title":"Sci Adv"},{"key":"2477_CR303","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26:878\u201385.","journal-title":"Nat Med"},{"key":"2477_CR304","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4094-2","volume":"18","author":"SK Thomas","year":"2018","unstructured":"Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, et al. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer. 2018;18:187.","journal-title":"BMC Cancer"},{"key":"2477_CR305","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-22-1927","volume":"28","author":"P Hillemanns","year":"2022","unstructured":"Hillemanns P, Denecke A, Woelber L, B\u00f6hmer G, Jentschke M, Schjetne KW, et al. A therapeutic antigen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-positive high-grade cervical intraepithelial neoplasia: results from a phase I\/IIa trial. Clin Cancer Res. 2022;28:4885\u201392.","journal-title":"Clin Cancer Res"},{"key":"2477_CR306","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"2477_CR307","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145\u20137.","journal-title":"Nat Med"},{"key":"2477_CR308","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109:17561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR309","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1316437","volume":"6","author":"C Secondini","year":"2017","unstructured":"Secondini C, Coquoz O, Spagnuolo L, Spinetti T, Peyvandi S, Ciarloni L, et al. Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. Oncoimmunology. 2017;6:e1316437.","journal-title":"Oncoimmunology"},{"key":"2477_CR310","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0403-1","volume":"6","author":"Y Tada","year":"2018","unstructured":"Tada Y, Togashi Y, Kotani D, Kuwata T, Sato E, Kawazoe A, et al. Targeting VEGFR2 with Ramucirumab strongly impacts effector\/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment. J Immunother Cancer. 2018;6:106.","journal-title":"J Immunother Cancer"},{"key":"2477_CR311","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.22.00221","volume":"41","author":"A Arance","year":"2023","unstructured":"Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol. 2023;41:75\u201385.","journal-title":"J Clin Oncol"},{"key":"2477_CR312","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212577","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang J, Guo Z, Song M, Pan Q, Zhao J, Huang Y, et al. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFR\u03b2 complex in hepatocellular carcinoma. Front Immunol. 2023;14:1212577.","journal-title":"Front Immunol"},{"key":"2477_CR313","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157347","volume":"8","author":"TT Tran","year":"2023","unstructured":"Tran TT, Caulfield J, Zhang L, Schoenfeld D, Djureinovic D, Chiang VL, et al. Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma. JCI Insight. 2023;8:e157347.","journal-title":"JCI Insight"},{"key":"2477_CR314","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00390-x","volume":"3","author":"M Yamauchi","year":"2023","unstructured":"Yamauchi M, Ono A, Amioka K, Fujii Y, Nakahara H, Teraoka Y, et al. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma. Commun Med. 2023;3:152.","journal-title":"Commun Med"},{"key":"2477_CR315","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1073\/pnas.1525360113","volume":"113","author":"J Kloepper","year":"2016","unstructured":"Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, et al. Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016;113:4476\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR316","doi-asserted-by":"publisher","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel M, Rigamonti N, Kadioglu E, Cassar\u00e1 A, Wyser Rmili C, Kiialainen A, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9:eaak9670.","journal-title":"Sci Transl Med"},{"key":"2477_CR317","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1073\/pnas.1525349113","volume":"113","author":"TE Peterson","year":"2016","unstructured":"Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A. 2016;113:4470\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR318","doi-asserted-by":"publisher","first-page":"16618","DOI":"10.1073\/pnas.1117610109","volume":"109","author":"J Liu","year":"2012","unstructured":"Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, et al. TGF-\u03b2 blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A. 2012;109:16618\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR319","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.7150\/thno.36936","volume":"10","author":"M Panagi","year":"2020","unstructured":"Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, et al. TGF-\u03b2 inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics. 2020;10:1910\u201322.","journal-title":"Theranostics"},{"key":"2477_CR320","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, et al. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov. 2022;12:108\u201333.","journal-title":"Cancer Discov"},{"key":"2477_CR321","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc7609","volume":"7","author":"JN Cheng","year":"2021","unstructured":"Cheng JN, Luo W, Sun C, Jin Z, Zeng X, Alexander PB, et al. Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy. Sci Adv. 2021;7:eabc7609.","journal-title":"Sci Adv"},{"key":"2477_CR322","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1073\/pnas.1700340114","volume":"114","author":"F Mpekris","year":"2017","unstructured":"Mpekris F, Baish JW, Stylianopoulos T, Jain RK. Role of vascular normalization in benefit from metronomic chemotherapy. Proc Natl Acad Sci U S A. 2017;114:1994\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR323","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/sj.bjc.6604352","volume":"98","author":"G Bocci","year":"2008","unstructured":"Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer. 2008;98:1619\u201329.","journal-title":"Br J Cancer"},{"key":"2477_CR324","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","volume":"30","author":"AR Cantelmo","year":"2016","unstructured":"Cantelmo AR, Conradi LC, Brajic A, Goveia J, Kalucka J, Pircher A, et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell. 2016;30:968\u201385.","journal-title":"Cancer Cell"},{"key":"2477_CR325","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002151","volume":"9","author":"E Lanitis","year":"2021","unstructured":"Lanitis E, Kosti P, Ronet C, Cribioli E, Rota G, Spill A, et al. Vegfr-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. J Immunother Cancer. 2021;9:e002151.","journal-title":"J Immunother Cancer"},{"key":"2477_CR326","doi-asserted-by":"publisher","first-page":"eadg3840","DOI":"10.1126\/scitranslmed.adg3840","volume":"16","author":"JJF Sleeboom","year":"2024","unstructured":"Sleeboom JJF, van Tienderen GS, Schenke-Layland K, van der Laan LJW, Khalil AA, and Verstegen MMA. The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets. Sci Transl Med. 2024;16:eadg3840.","journal-title":"Sci Transl Med"},{"key":"2477_CR327","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02070-x","volume":"40","author":"L Morosi","year":"2021","unstructured":"Morosi L, Meroni M, Ubezio P, Fuso Nerini I, Minoli L, Porcu L, et al. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. J Exp Clin Cancer Res. 2021;40:286.","journal-title":"J Exp Clin Cancer Res"},{"key":"2477_CR328","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/oncolo\/oyad022","volume":"28","author":"AH Ko","year":"2023","unstructured":"Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O\u2019Reilly EM, et al. Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib\/II umbrella randomized study platform. Oncologist. 2023;28:553-e472.","journal-title":"Oncologist"},{"key":"2477_CR329","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58688","author":"A Nicolas-Boluda","year":"2021","unstructured":"Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife. 2021. https:\/\/doi.org\/10.7554\/eLife.58688.","journal-title":"Elife"},{"key":"2477_CR330","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.matbio.2019.02.003","volume":"85\u201386","author":"HC Pruitt","year":"2020","unstructured":"Pruitt HC, Lewis D, Ciccaglione M, Connor S, Smith Q, Hickey JW, et al. Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes. Matrix Biol. 2020;85\u201386:147\u201359.","journal-title":"Matrix Biol"},{"key":"2477_CR331","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009327","volume":"12","author":"J Mei","year":"2024","unstructured":"Mei J, Chu J, Yang K, Luo Z, Yang J, Xu J, et al. Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. J Immunother Cancer. 2024;12:e009327.","journal-title":"J Immunother Cancer"},{"key":"2477_CR332","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.","journal-title":"Nat Commun"},{"key":"2477_CR333","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-021-04057-2","volume":"599","author":"X Sun","year":"2021","unstructured":"Sun X, Wu B, Chiang HC, Deng H, Zhang X, Xiong W, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 2021;599:673\u20138.","journal-title":"Nature"},{"key":"2477_CR334","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/path.6422","volume":"266","author":"L Li","year":"2025","unstructured":"Li L, Xie S, Zhou J, Ran J. Utilizing aptamers in targeted protein degradation strategies for disease therapy. J Pathol. 2025;266:134\u201343.","journal-title":"J Pathol"},{"key":"2477_CR335","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343.","journal-title":"Nature"},{"key":"2477_CR336","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","volume":"39","author":"H Hu","year":"2021","unstructured":"Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, et al. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021;39:1531-47.e10.","journal-title":"Cancer Cell"},{"key":"2477_CR337","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Ther. 2024;9:68.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR338","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41577-024-01112-7","volume":"25","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zhang C. Regulation of cGAS-STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. 2025;25:425\u201344.","journal-title":"Nat Rev Immunol"},{"key":"2477_CR339","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02380-0","volume":"24","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yu Y, Zhuang J, Liu R, Sun C. Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment. Mol Cancer. 2025;24:178.","journal-title":"Mol Cancer"},{"key":"2477_CR340","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","volume":"187","author":"MB Maxwell","year":"2024","unstructured":"Maxwell MB, Hom-Tedla MS, Yi J, Li S, Rivera SA, Yu J, et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell. 2024;187:3390-408.e19.","journal-title":"Cell"},{"key":"2477_CR341","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.immuni.2024.02.019","volume":"57","author":"S Dvorkin","year":"2024","unstructured":"Dvorkin S, Cambier S, Volkman HE, Stetson DB. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity. 2024;57:718\u201330.","journal-title":"Immunity"},{"key":"2477_CR342","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41586-021-04009-w","volume":"599","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang M, Djekidel MN, Chen H, Liu D, Alt FW, et al. EccDNAs are apoptotic products with high innate immunostimulatory activity. Nature. 2021;599:308\u201314.","journal-title":"Nature"},{"key":"2477_CR343","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1126\/science.aat1022","volume":"361","author":"M Du","year":"2018","unstructured":"Du M, Chen ZJ. DNA-induced liquid phase condensation of cGAS activates innate immune signaling. Science. 2018;361:704\u20139.","journal-title":"Science"},{"key":"2477_CR344","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.molcel.2021.01.024","volume":"81","author":"W Zhou","year":"2021","unstructured":"Zhou W, Mohr L, Maciejowski J, Kranzusch PJ. cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing. Mol Cell. 2021;81:739-55.e7.","journal-title":"Mol Cell"},{"key":"2477_CR345","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41590-018-0287-8","volume":"20","author":"S Srikanth","year":"2019","unstructured":"Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, et al. The Ca(2+) sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. Nat Immunol. 2019;20:152\u201362.","journal-title":"Nat Immunol"},{"key":"2477_CR346","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41586-019-1000-2","volume":"567","author":"C Zhang","year":"2019","unstructured":"Zhang C, Shang G, Gui X, Zhang X, Bai XC, Chen ZJ. Structural basis of STING binding with and phosphorylation by TBK1. Nature. 2019;567:394\u20138.","journal-title":"Nature"},{"key":"2477_CR347","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41586-019-1228-x","volume":"569","author":"B Zhao","year":"2019","unstructured":"Zhao B, Du F, Xu P, Shu C, Sankaran B, Bell SL, et al. A conserved PLPLRT\/SD motif of STING mediates the recruitment and activation of TBK1. Nature. 2019;569:718\u201322.","journal-title":"Nature"},{"key":"2477_CR348","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2100225118","volume":"118","author":"S Yum","year":"2021","unstructured":"Yum S, Li M, Fang Y, Chen ZJ. TBK1 recruitment to STING activates both IRF3 and NF-\u03baB that mediate immune defense against tumors and viral infections. Proc Natl Acad Sci USA. 2021;118:e2100225118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2477_CR349","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cell.2019.05.036","volume":"178","author":"SL Ergun","year":"2019","unstructured":"Ergun SL, Fernandez D, Weiss TM, Li L. Sting polymer structure reveals mechanisms for activation, hyperactivation, and inhibition. Cell. 2019;178:290-301.e10.","journal-title":"Cell"},{"issue":"97","key":"2477_CR350","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adm8185","volume":"9","author":"YJ Crow","year":"2024","unstructured":"Crow YJ, Casanova JL. Human life within a narrow range: the lethal ups and downs of type I interferons. Sci Immunol. 2024;9(97):eadm8185.","journal-title":"Sci Immunol"},{"key":"2477_CR351","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112185","volume":"42","author":"L Zhang","year":"2023","unstructured":"Zhang L, Wei X, Wang Z, Liu P, Hou Y, Xu Y, et al. NF-\u03baB activation enhances STING signaling by altering microtubule-mediated STING trafficking. Cell Rep. 2023;42:112185.","journal-title":"Cell Rep"},{"key":"2477_CR352","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1126\/science.aab3632","volume":"349","author":"A Bridgeman","year":"2015","unstructured":"Bridgeman A, Maelfait J, Davenne T, Partridge T, Peng Y, Mayer A, et al. Viruses transfer the antiviral second messenger cGAMP between cells. Science. 2015;349:1228\u201332.","journal-title":"Science"},{"key":"2477_CR353","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-019-1553-0","volume":"573","author":"RD Luteijn","year":"2019","unstructured":"Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, et al. SLC19A1 transports immunoreactive cyclic dinucleotides. Nature. 2019;573:434\u20138.","journal-title":"Nature"},{"key":"2477_CR354","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1021\/acscentsci.1c00440","volume":"7","author":"AF Cordova","year":"2021","unstructured":"Cordova AF, Ritchie C, B\u00f6hnert V, Li L. Human SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-sensing macrophages and monocytes. ACS Cent Sci. 2021;7:1073\u201388.","journal-title":"ACS Cent Sci"},{"key":"2477_CR355","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.immuni.2020.03.016","volume":"52","author":"C Zhou","year":"2020","unstructured":"Zhou C, Chen X, Planells-Cases R, Chu J, Wang L, Cao L, et al. Transfer of cGAMP into Bystander Cells via LRRC8 Volume-Regulated Anion Channels Augments STING-Mediated Interferon Responses and Anti-viral Immunity. Immunity. 2020;52:767-81.e6.","journal-title":"Immunity"},{"key":"2477_CR356","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity. 2018;49:754-63.e4.","journal-title":"Immunity"},{"key":"2477_CR357","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s43018-020-0028-4","volume":"1","author":"JA Carozza","year":"2020","unstructured":"Carozza JA, B\u00f6hnert V, Nguyen KC, Skariah G, Shaw KE, Brown JA, et al. Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity. Nat Cancer. 2020;1:184\u201396.","journal-title":"Nat Cancer"},{"key":"2477_CR358","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843\u201352.","journal-title":"Immunity"},{"key":"2477_CR359","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830\u201342.","journal-title":"Immunity"},{"key":"2477_CR360","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201899238","author":"JS Riley","year":"2018","unstructured":"Riley JS, Quarato G, Cloix C, Lopez J, O\u2019Prey J, Pearson M, et al. Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis. EMBO J. 2018. https:\/\/doi.org\/10.15252\/embj.201899238.","journal-title":"EMBO J"},{"key":"2477_CR361","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao6047","volume":"359","author":"K McArthur","year":"2018","unstructured":"McArthur K, Whitehead LW, Heddleston JM, Li L, Padman BS, Oorschot V, et al. BAK\/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science. 2018;359:eaao6047.","journal-title":"Science"},{"key":"2477_CR362","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature14156","volume":"520","author":"AP West","year":"2015","unstructured":"West AP, Khoury-Hanold W, Staron M, Tal MC, Pineda CM, Lang SM, et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553\u20137.","journal-title":"Nature"},{"key":"2477_CR363","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nchembio.1661","volume":"10","author":"L Li","year":"2014","unstructured":"Li L, Yin Q, Kuss P, Maliga Z, Mill\u00e1n JL, Wu H, et al. Hydrolysis of 2\u20193\u2019-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol. 2014;10:1043\u20138.","journal-title":"Nat Chem Biol"},{"key":"2477_CR364","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41586-024-07112-w","volume":"627","author":"P Xu","year":"2024","unstructured":"Xu P, Liu Y, Liu C, Guey B, Li L, Melenec P, et al. The CRL5-SPSB3 ubiquitin ligase targets nuclear cGAS for degradation. Nature. 2024;627:873\u20139.","journal-title":"Nature"},{"key":"2477_CR365","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201045","volume":"217","author":"Z Deng","year":"2020","unstructured":"Deng Z, Chong Z, Law CS, Mukai K, Ho FO, Martinu T, et al. A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome. J Exp Med. 2020;217:e20201045.","journal-title":"J Exp Med"},{"key":"2477_CR366","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42150-4","volume":"14","author":"M Hirschenberger","year":"2023","unstructured":"Hirschenberger M, Lepelley A, Rupp U, Klute S, Hunszinger V, Koepke L, et al. ARF1 prevents aberrant type i interferon induction by regulating STING activation and recycling. Nat Commun. 2023;14:6770.","journal-title":"Nat Commun"},{"key":"2477_CR367","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.aaw6421","volume":"369","author":"B Guey","year":"2020","unstructured":"Guey B, Wischnewski M, Decout A, Makasheva K, Kaynak M, Sakar MS, et al. BAF restricts cGAS on nuclear DNA to prevent innate immune activation. Science. 2020;369:823\u20138.","journal-title":"Science"},{"key":"2477_CR368","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41590-024-01872-3","volume":"25","author":"KRB Lanng","year":"2024","unstructured":"Lanng KRB, Lauridsen EL, Jakobsen MR. The balance of STING signaling orchestrates immunity in cancer. Nat Immunol. 2024;25:1144\u201357.","journal-title":"Nat Immunol"},{"key":"2477_CR369","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s43018-024-00736-x","volume":"5","author":"H Dong","year":"2024","unstructured":"Dong H, He X, Zhang L, Chen W, Lin YC, Liu SB, et al. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024;5:601\u201324.","journal-title":"Nat Cancer"},{"key":"2477_CR370","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404432","volume":"12","author":"J Luo","year":"2025","unstructured":"Luo J, Wang S, Yang Q, Fu Q, Zhu C, Li T, et al. \u03b3\u03b4 T Cell-mediated Tumor Immunity is Tightly Regulated by STING and TGF-\u03b2 Signaling Pathways. Adv Sci (Weinh). 2025;12:e2404432.","journal-title":"Adv Sci (Weinh)"},{"key":"2477_CR371","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","volume":"28","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas. Clin Cancer Res. 2022;28:677\u201388.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2477_CR372","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1021\/acs.jmedchem.1c02197","volume":"65","author":"W Chang","year":"2022","unstructured":"Chang W, Altman MD, Lesburg CA, Perera SA, Piesvaux JA, Schroeder GK, et al. Discovery of MK-1454: a potent cyclic dinucleotide stimulator of interferon genes agonist for the treatment of cancer. J Med Chem. 2022;65(7):5675\u201389.","journal-title":"J Med Chem"},{"key":"2477_CR373","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","volume":"564","author":"JM Ramanjulu","year":"2018","unstructured":"Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564:439\u201343.","journal-title":"Nature"},{"key":"2477_CR374","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6098","volume":"369","author":"BS Pan","year":"2020","unstructured":"Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369:eaba6098.","journal-title":"Science"},{"key":"2477_CR375","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","volume":"30","author":"M Lv","year":"2020","unstructured":"Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020;30:966\u201379.","journal-title":"Cell Res"},{"key":"2477_CR376","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.freeradbiomed.2022.10.004","volume":"193","author":"S Zhang","year":"2022","unstructured":"Zhang S, Kang L, Dai X, Chen J, Chen Z, Wang M, et al. Manganese induces tumor cell ferroptosis through type-I IFN dependent inhibition of mitochondrial dihydroorotate dehydrogenase. Free Radic Biol Med. 2022;193:202\u201312.","journal-title":"Free Radic Biol Med"},{"key":"2477_CR377","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.753472","volume":"12","author":"KM Garland","year":"2021","unstructured":"Garland KM, Rosch JC, Carson CS, Wang-Bishop L, Hanna A, Sevimli S, et al. Pharmacological activation of cGAS for cancer immunotherapy. Front Immunol. 2021;12:753472.","journal-title":"Front Immunol"},{"key":"2477_CR378","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","volume":"29","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, et al. Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study. Clin Cancer Res. 2023;29:110\u201321.","journal-title":"Clin Cancer Res"},{"key":"2477_CR379","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47692-9","volume":"15","author":"U Uslu","year":"2024","unstructured":"Uslu U, Sun L, Castelli S, Finck AV, Assenmacher CA, Young RM, et al. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. Nat Commun. 2024;15:3933.","journal-title":"Nat Commun"},{"key":"2477_CR380","first-page":"551","volume":"62","author":"Y Douville","year":"1978","unstructured":"Douville Y, Pelouze G, Roy R, Charrois R, Kibrit\u00e9 A, Martin M, et al. Recurrent bladder papillomata treated with bacillus Calmette-Gu\u00e9rin: a preliminary report (phase I trial). Cancer Treat Rep. 1978;62:551\u20132.","journal-title":"Cancer Treat Rep"},{"key":"2477_CR381","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","volume":"126","author":"AH Rook","year":"2015","unstructured":"Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126:1452\u201361.","journal-title":"Blood"},{"key":"2477_CR382","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ijc.28413","volume":"134","author":"L Belmont","year":"2014","unstructured":"Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Kurie J, et al. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. Int J Cancer. 2014;134:765\u201377.","journal-title":"Int J Cancer"},{"key":"2477_CR383","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.jtho.2019.07.023","volume":"14","author":"SD Gowing","year":"2019","unstructured":"Gowing SD, Chow SC, Cools-Lartigue JJ, Chen CB, Najmeh S, Goodwin-Wilson M, et al. Gram-negative pneumonia augments non-small cell lung cancer metastasis through host toll-like receptor 4 activation. J Thorac Oncol. 2019;14:2097\u2013108.","journal-title":"J Thorac Oncol"},{"key":"2477_CR384","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/gutjnl-2020-323426","volume":"71","author":"W Si","year":"2022","unstructured":"Si W, Liang H, Bugno J, Xu Q, Ding X, Yang K, et al. Lactobacillus rhamnosus GG induces cGAS\/STING-dependent type i interferon and improves response to immune checkpoint blockade. Gut. 2022;71:521\u201333.","journal-title":"Gut"},{"key":"2477_CR385","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01304-4","volume":"8","author":"L Yang","year":"2023","unstructured":"Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023;8:35.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR386","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20:171.","journal-title":"Mol Cancer"},{"key":"2477_CR387","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-3","volume":"2","author":"S Spranger","year":"2014","unstructured":"Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:3.","journal-title":"J Immunother Cancer"},{"key":"2477_CR388","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","volume":"170","author":"HE Ghoneim","year":"2017","unstructured":"Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017;170:142-57.e19.","journal-title":"Cell"},{"key":"2477_CR389","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-20-0285","volume":"80","author":"TA Gonda","year":"2020","unstructured":"Gonda TA, Fang J, Salas M, Do C, Hsu E, Zhukovskaya A, et al. A DNA hypomethylating drug alters the tumor microenvironment and improves the effectiveness of immune checkpoint inhibitors in a mouse model of pancreatic cancer. Cancer Res. 2020;80:4754\u201367.","journal-title":"Cancer Res"},{"key":"2477_CR390","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","volume":"2","author":"KL Morel","year":"2021","unstructured":"Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. Ezh2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2:444\u201356.","journal-title":"Nat Cancer"},{"key":"2477_CR391","doi-asserted-by":"publisher","first-page":"eaaz5387","DOI":"10.1126\/scitranslmed.aaz5387","volume":"12","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yao J, Wei Y, Zhou Z, Li P, Qu J, et al. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Sci Transl Med. 2020;12:eaaz5387.","journal-title":"Sci Transl Med"},{"key":"2477_CR392","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C, Ding W, Tillement O, Bai H, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther. 2025;10:219.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR393","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018;174:549-63.e19.","journal-title":"Cell"},{"key":"2477_CR394","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/10428194.2021.2012667","volume":"63","author":"GJ Roboz","year":"2022","unstructured":"Roboz GJ, Yee K, Verma A, Borthakur G, de la Fuente Burguera A, Sanz G, et al. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed\/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Lymphoma. 2022;63:463\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2477_CR395","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1038\/s41467-022-34253-1","volume":"13","author":"H Ning","year":"2022","unstructured":"Ning H, Huang S, Lei Y, Zhi R, Yan H, Jin J, et al. Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. Nat Commun. 2022;13:6578.","journal-title":"Nat Commun"},{"key":"2477_CR396","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112823","volume":"42","author":"N Nigam","year":"2023","unstructured":"Nigam N, Bernard B, Sevilla S, Kim S, Dar MS, Tsai D, et al. SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. Cell Rep. 2023;42:112823.","journal-title":"Cell Rep"},{"key":"2477_CR397","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4492","volume":"386","author":"TG Kang","year":"2024","unstructured":"Kang TG, Lan X, Mi T, Chen H, Alli S, Lim SE, et al. Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy. Science. 2024;386:eadl4492.","journal-title":"Science"},{"key":"2477_CR398","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","volume":"13","author":"S Ma","year":"2022","unstructured":"Ma S, Zhao Y, Lee WC, Ong LT, Lee PL, Jiang Z, et al. Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nat Commun. 2022;13:4118.","journal-title":"Nat Commun"},{"key":"2477_CR399","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1038\/s41467-021-27179-7","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Debo B, Li M, Shi Z, Sheng W, Shi Y. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. Nat Commun. 2021;12:6831.","journal-title":"Nat Commun"},{"key":"2477_CR400","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.jtho.2019.06.021","volume":"14","author":"TM Bauer","year":"2019","unstructured":"Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, Garrido P, et al. Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed\/refractory SCLC. J Thorac Oncol. 2019;14:1828\u201338.","journal-title":"J Thorac Oncol"},{"key":"2477_CR401","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","volume":"183","author":"L Kalafati","year":"2020","unstructured":"Kalafati L, Kourtzelis I, Schulte-Schrepping J, Li X, Hatzioannou A, Grinenko T, et al. Innate Immune Training of Granulopoiesis Promotes Anti-tumor Activity. Cell. 2020;183:771-85.e12.","journal-title":"Cell"},{"key":"2477_CR402","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1053\/j.gastro.2023.04.032","volume":"165","author":"J Zhai","year":"2023","unstructured":"Zhai J, Chen H, Wong CC, Peng Y, Gou H, Zhang J, et al. Alkbh5 drives immune suppression via targeting AXIN2 to promote colorectal cancer and is a target for boosting immunotherapy. Gastroenterology. 2023;165:445\u201362.","journal-title":"Gastroenterology"},{"key":"2477_CR403","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","volume":"81","author":"X Qiu","year":"2021","unstructured":"Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, et al. M(6)a demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma. Cancer Res. 2021;81:4778\u201393.","journal-title":"Cancer Res"},{"key":"2477_CR404","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","volume":"10","author":"H Jung","year":"2019","unstructured":"Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019;10:4278.","journal-title":"Nat Commun"},{"key":"2477_CR405","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-0808-9","volume":"12","author":"V Sasidharan Nair","year":"2020","unstructured":"Sasidharan Nair V, Saleh R, Toor SM, Taha RZ, Ahmed AA, Kurer MA, et al. Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. Clin Epigenetics. 2020;12:13.","journal-title":"Clin Epigenetics"},{"key":"2477_CR406","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.trecan.2022.06.005","volume":"8","author":"M Casado-Pelaez","year":"2022","unstructured":"Casado-Pelaez M, Bueno-Costa A, Esteller M. Single cell cancer epigenetics. Trends Cancer. 2022;8:820\u201338.","journal-title":"Trends Cancer"},{"key":"2477_CR407","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1158\/0008-5472.CAN-22-2224","volume":"83","author":"Z Yu","year":"2023","unstructured":"Yu Z, Lv Y, Su C, Lu W, Zhang R, Li J, et al. Integrative single-cell analysis reveals transcriptional and epigenetic regulatory features of clear cell renal cell carcinoma. Cancer Res. 2023;83:700\u201319.","journal-title":"Cancer Res"},{"key":"2477_CR408","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20723-x","volume":"12","author":"Z Wei","year":"2021","unstructured":"Wei Z, Zhang X, Yong T, Bie N, Zhan G, Li X, et al. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nat Commun. 2021;12:440.","journal-title":"Nat Commun"},{"key":"2477_CR409","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121:837\u201345.","journal-title":"Br J Cancer"},{"key":"2477_CR410","doi-asserted-by":"publisher","first-page":"eabn1128","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L, et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022;14:eabn1128.","journal-title":"Sci Transl Med"},{"key":"2477_CR411","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1158\/1538-7445.AM2021-63","volume":"81","author":"S Pierini","year":"2021","unstructured":"Pierini S, Gabbasov R, Gabitova L, Ohtani Y, Shestova O, Gill S, et al. Abstract 63: chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models. Cancer Res. 2021;81:63\u201363.","journal-title":"Cancer Res"},{"key":"2477_CR412","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1158\/1078-0432.CCR-16-1784","volume":"23","author":"GA Dominguez","year":"2017","unstructured":"Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin Cancer Res. 2017;23:2942\u201350.","journal-title":"Clin Cancer Res"},{"key":"2477_CR413","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","volume":"30","author":"P Cheng","year":"2022","unstructured":"Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, et al. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022;30:2315\u201326.","journal-title":"Mol Ther"},{"key":"2477_CR414","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17:651\u201362.","journal-title":"Lancet Oncol"},{"key":"2477_CR415","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055718","volume":"12","author":"T Nishina","year":"2022","unstructured":"Nishina T, Fujita T, Yoshizuka N, Sugibayashi K, Murayama K, Kuboki Y. Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study. BMJ Open. 2022;12:e055718.","journal-title":"BMJ Open"},{"key":"2477_CR416","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1158\/1078-0432.CCR-22-2495","volume":"29","author":"RP Tobin","year":"2023","unstructured":"Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, et al. Targeting MDSC differentiation using ATRA: a phase I\/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma. Clin Cancer Res. 2023;29:1209\u201319.","journal-title":"Clin Cancer Res"},{"key":"2477_CR417","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105557","volume":"198","author":"JC Fleet","year":"2020","unstructured":"Fleet JC, Burcham GN, Calvert RD, Elzey BD, Ratliff TL. 1\u03b1, 25 dihydroxyvitamin D (1,25(OH)(2)D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC). J Steroid Biochem Mol Biol. 2020;198:105557.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2477_CR418","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/ijc.28168","volume":"133","author":"B Schilling","year":"2013","unstructured":"Schilling B, Sucker A, Griewank K, Zhao F, Weide B, G\u00f6rgens A, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer. 2013;133:1653\u201363.","journal-title":"Int J Cancer"},{"key":"2477_CR419","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008081","volume":"11","author":"L Wu","year":"2023","unstructured":"Wu L, Liu X, Lei J, Zhang N, Zhao H, Zhang J, et al. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells. J Immunother Cancer. 2023;11:e008081.","journal-title":"J Immunother Cancer"},{"key":"2477_CR420","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-023-06511-9","volume":"621","author":"C Wang","year":"2023","unstructured":"Wang C, Zheng X, Zhang J, Jiang X, Wang J, Li Y, et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023;621:830\u20139.","journal-title":"Nature"},{"key":"2477_CR421","doi-asserted-by":"publisher","first-page":"eabb0130","DOI":"10.1126\/scitranslmed.abb0130","volume":"13","author":"Y Hou","year":"2021","unstructured":"Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, et al. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021;13:eabb0130.","journal-title":"Sci Transl Med"},{"key":"2477_CR422","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1172\/JCI97973","volume":"128","author":"C Wu","year":"2018","unstructured":"Wu C, Ning H, Liu M, Lin J, Luo S, Zhu W, et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest. 2018;128:3425\u201338.","journal-title":"J Clin Invest"},{"key":"2477_CR423","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/cancers13081793","volume":"13","author":"S Ito","year":"2021","unstructured":"Ito S, Sato T, Maeta T. Role and Therapeutic Targeting of SDF-1\u03b1\/CXCR4 Axis in Multiple Myeloma. Cancers (Basel). 2021;13:1793.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2477_CR424","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01145-w","volume":"21","author":"T Yuan","year":"2023","unstructured":"Yuan T, Jia Q, Zhu B, Chen D, Long H. Synergistic immunotherapy targeting cancer-associated anemia: prospects of a combination strategy. Cell Commun Signal. 2023;21(1):117.","journal-title":"Cell Commun Signal"},{"key":"2477_CR425","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200164","volume":"217","author":"JW Swann","year":"2020","unstructured":"Swann JW, Koneva LA, Regan-Komito D, Sansom SN, Powrie F, Griseri T. IL-33 promotes anemia during chronic inflammation by inhibiting differentiation of erythroid progenitors. J Exp Med. 2020;217:e20200164.","journal-title":"J Exp Med"},{"key":"2477_CR426","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-02120-9","volume":"12","author":"B Wang","year":"2021","unstructured":"Wang B, Wang Y, Chen H, Yao S, Lai X, Qiu Y, et al. Inhibition of TGF\u03b2 improves hematopoietic stem cell niche and ameliorates cancer-related anemia. Stem Cell Res Ther. 2021;12:65.","journal-title":"Stem Cell Res Ther"},{"key":"2477_CR427","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006595","volume":"11","author":"N Bozorgmehr","year":"2023","unstructured":"Bozorgmehr N, Okoye I, Mashhouri S, Lu J, Koleva P, Walker J, et al. CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors. J Immunother Cancer. 2023;11:e006595.","journal-title":"J Immunother Cancer"},{"key":"2477_CR428","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, et al. Cxcr2 inhibition enables NASH-HCC immunotherapy. Gut. 2022;71:2093\u2013106.","journal-title":"Gut"},{"key":"2477_CR429","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216185","volume":"563","author":"DR Prajapati","year":"2023","unstructured":"Prajapati DR, Molczyk C, Purohit A, Saxena S, Sturgeon R, Dave BJ, et al. Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. Cancer Lett. 2023;563:216185.","journal-title":"Cancer Lett"},{"key":"2477_CR430","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.7150\/jca.38179","volume":"11","author":"F Qin","year":"2020","unstructured":"Qin F, Liu X, Chen J, Huang S, Wei W, Zou Y, et al. Anti-TGF-\u03b2 attenuates tumor growth via polarization of tumor associated neutrophils towards an anti-tumor phenotype in colorectal cancer. J Cancer. 2020;11:2580\u201392.","journal-title":"J Cancer"},{"key":"2477_CR431","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1811605","volume":"9","author":"R Greco","year":"2020","unstructured":"Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, et al. Pan-TGF\u03b2 inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. Oncoimmunology. 2020;9:1811605.","journal-title":"Oncoimmunology"},{"key":"2477_CR432","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000249","volume":"3","author":"A Naing","year":"2024","unstructured":"Naing A, Papadopoulos KP, Pishvaian MJ, Rahma O, Hanna GJ, Garralda E, et al. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. BMJ Oncol. 2024;3:e000249.","journal-title":"BMJ Oncol"},{"key":"2477_CR433","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add9990","volume":"15","author":"V Juric","year":"2023","unstructured":"Juric V, Mayes E, Binnewies M, Lee T, Canaday P, Pollack JL, et al. TREM1 activation of myeloid cells promotes antitumor immunity. Sci Transl Med. 2023;15:eadd9990.","journal-title":"Sci Transl Med"},{"key":"2477_CR434","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375:eabf9419.","journal-title":"Science"},{"key":"2477_CR435","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70046","volume":"332","author":"J Rochefort","year":"2025","unstructured":"Rochefort J, Marodon G, Teillaud JL, Dieu-Nosjean MC. The sunrise of tertiary lymphoid structures in cancer. Immunol Rev. 2025;332:e70046.","journal-title":"Immunol Rev"},{"key":"2477_CR436","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.933113","volume":"10","author":"A Rossi","year":"2022","unstructured":"Rossi A, Belmonte B, Carnevale S, Liotti A, De Rosa V, Jaillon S, et al. Stromal and immune cell dynamics in tumor associated tertiary lymphoid structures and anti-tumor immune responses. Front Cell Dev Biol. 2022;10:933113.","journal-title":"Front Cell Dev Biol"},{"key":"2477_CR437","doi-asserted-by":"publisher","first-page":"13490","DOI":"10.1073\/pnas.1905301116","volume":"116","author":"S Nayar","year":"2019","unstructured":"Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Mourcin F, et al. Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proc Natl Acad Sci U S A. 2019;116:13490\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR438","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18916-5","volume":"11","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zhou L, Liu L, Hou Y, Xiong M, Yang Y, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11:5077.","journal-title":"Nat Commun"},{"key":"2477_CR439","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-21-1130","volume":"28","author":"M Lauss","year":"2022","unstructured":"Lauss M, Donia M, Svane IM, J\u00f6nsson G. B cells and tertiary lymphoid structures: friends or foes in cancer immunotherapy? Clin Cancer Res. 2022;28:1751\u20138.","journal-title":"Clin Cancer Res"},{"key":"2477_CR440","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nri3689","volume":"14","author":"BA Heesters","year":"2014","unstructured":"Heesters BA, Myers RC, Carroll MC. Follicular dendritic cells: dynamic antigen libraries. Nat Rev Immunol. 2014;14:495\u2013504.","journal-title":"Nat Rev Immunol"},{"key":"2477_CR441","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.it.2024.12.007","volume":"46","author":"T Llorca","year":"2025","unstructured":"Llorca T, Ruiz-Maga\u00f1a MJ, Abad\u00eda AC, Ruiz-Ruiz C, Olivares EG. Decidual stromal cells: fibroblasts specialized in immunoregulation during pregnancy. Trends Immunol. 2025;46:138\u201352.","journal-title":"Trends Immunol"},{"key":"2477_CR442","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman WH, Meylan M, Pupier G, Calvez A, Hernandez I, Saut\u00e8s-Fridman C. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity. 2023;56:2254\u201369.","journal-title":"Immunity"},{"key":"2477_CR443","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/07853890.2022.2153911","volume":"55","author":"Z Zhan","year":"2023","unstructured":"Zhan Z, Shi-Jin L, Yi-Ran Z, Zhi-Long L, Xiao-Xu Z, Hui D, et al. High endothelial venules proportion in tertiary lymphoid structure is a prognostic marker and correlated with anti-tumor immune microenvironment in colorectal cancer. Ann Med. 2023;55:114\u201326.","journal-title":"Ann Med"},{"key":"2477_CR444","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ccell.2023.02.002","volume":"41","author":"G Vella","year":"2023","unstructured":"Vella G, Hua Y, Bergers G. High endothelial venules in cancer: regulation, function, and therapeutic implication. Cancer Cell. 2023;41:527\u201345.","journal-title":"Cancer Cell"},{"key":"2477_CR445","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41581-023-00706-z","volume":"19","author":"Y Sato","year":"2023","unstructured":"Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M. The roles of tertiary lymphoid structures in chronic diseases. Nat Rev Nephrol. 2023;19:525\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"2477_CR446","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/2326-6066.CIR-18-0517","volume":"7","author":"HH Workel","year":"2019","unstructured":"Workel HH, Lubbers JM, Arnold R, Prins TM, van der Vlies P, de Lange K, et al. A transcriptionally distinct CXCL13(+)CD103(+)CD8(+) T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol Res. 2019;7:784\u201396.","journal-title":"Cancer Immunol Res"},{"key":"2477_CR447","doi-asserted-by":"publisher","first-page":"1031746","DOI":"10.3389\/fimmu.2022.1031746","volume":"13","author":"M Vlaming","year":"2022","unstructured":"Vlaming M, Bilemjian V, Freile J, Melo V, Plat A, Huls G, et al. Tumor infiltrating CD8\/CD103\/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival. Front Immunol. 2022;13:1031746.","journal-title":"Front Immunol"},{"key":"2477_CR448","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006770","volume":"11","author":"L Koppensteiner","year":"2023","unstructured":"Koppensteiner L, Mathieson L, Pattle S, Dorward DA, O\u2019Connor R, Akram AR. Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer. J Immunother Cancer. 2023;11:e006770.","journal-title":"J Immunother Cancer"},{"key":"2477_CR449","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.immuni.2021.12.007","volume":"55","author":"RA Chaurio","year":"2022","unstructured":"Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, et al. TGF-\u03b2-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022;55:115-28.e9.","journal-title":"Immunity"},{"key":"2477_CR450","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1084\/jem.20091738","volume":"207","author":"MA Linterman","year":"2010","unstructured":"Linterman MA, Beaton L, Yu D, Ramiscal RR, Srivastava M, Hogan JJ, et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med. 2010;207:353\u201363.","journal-title":"J Exp Med"},{"key":"2477_CR451","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1164\/rccm.201906-1123OC","volume":"202","author":"T Naessens","year":"2020","unstructured":"Naessens T, Morias Y, Hamrud E, Gehrmann U, Budida R, Mattsson J, et al. Human lung conventional dendritic cells orchestrate lymphoid neogenesis during chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;202:535\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"2477_CR452","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101448","volume":"5","author":"W Liu","year":"2024","unstructured":"Liu W, You W, Lan Z, Ren Y, Gao S, Li S, et al. An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. Cell Rep Med. 2024;5:101448.","journal-title":"Cell Rep Med"},{"key":"2477_CR453","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1073\/pnas.1503315112","volume":"112","author":"F Barone","year":"2015","unstructured":"Barone F, Nayar S, Campos J, Cloake T, Withers DR, Toellner KM, et al. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc Natl Acad Sci U S A. 2015;112:11024\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR454","doi-asserted-by":"publisher","first-page":"105","DOI":"10.36401\/JIPO-22-10","volume":"5","author":"MB Ware","year":"2022","unstructured":"Ware MB, Wolfarth AA, Goon JB, Ezeanya UI, Dhar S, Ferrando-Martinez S, et al. The role of interleukin-7 in the formation of tertiary lymphoid structures and their prognostic value in gastrointestinal cancers. J Immunother Precis Oncol. 2022;5:105\u201317.","journal-title":"J Immunother Precis Oncol"},{"key":"2477_CR455","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.immuni.2005.10.002","volume":"23","author":"JL Browning","year":"2005","unstructured":"Browning JL, Allaire N, Ngam-Ek A, Notidis E, Hunt J, Perrin S, et al. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity. 2005;23:539\u201350.","journal-title":"Immunity"},{"key":"2477_CR456","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop. Cancer Cell. 2022;40:1600-18.e10.","journal-title":"Cancer Cell"},{"key":"2477_CR457","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1469-7580.2006.00650.x","volume":"209","author":"KS Blum","year":"2006","unstructured":"Blum KS, Pabst R. Keystones in lymph node development. J Anat. 2006;209:585\u201395.","journal-title":"J Anat"},{"key":"2477_CR458","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1016\/j.ymthe.2023.06.015","volume":"31","author":"N Zhang","year":"2023","unstructured":"Zhang N, Liu X, Qin J, Sun Y, Xiong H, Lin B, et al. LIGHT\/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment. Mol Ther. 2023;31:2575\u201390.","journal-title":"Mol Ther"},{"key":"2477_CR459","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Target Ther. 2024;9:225.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR460","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23355-x","volume":"12","author":"AT Ruffin","year":"2021","unstructured":"Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, et al. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun. 2021;12:3349.","journal-title":"Nat Commun"},{"key":"2477_CR461","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157215","volume":"7","author":"M Ukita","year":"2022","unstructured":"Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A, et al. Cxcl13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight. 2022;7:e157215.","journal-title":"JCI Insight"},{"key":"2477_CR462","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005531","volume":"10","author":"X Sun","year":"2022","unstructured":"Sun X, Liu W, Sun L, Mo H, Feng Y, Wu X, et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022;10:e005531.","journal-title":"J Immunother Cancer"},{"key":"2477_CR463","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-19-3211","volume":"26","author":"SS Kim","year":"2020","unstructured":"Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, et al. B cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade. Clin Cancer Res. 2020;26:3345\u201359.","journal-title":"Clin Cancer Res"},{"key":"2477_CR464","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2931-3","volume":"597","author":"A Wieland","year":"2021","unstructured":"Wieland A, Patel MR, Cardenas MA, Eberhardt CS, Hudson WH, Obeng RC, et al. Defining HPV-specific B cell responses in patients with head and neck cancer. Nature. 2021;597:274\u20138.","journal-title":"Nature"},{"key":"2477_CR465","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1346","volume":"13","author":"Q Wang","year":"2023","unstructured":"Wang Q, Sun K, Liu R, Song Y, Lv Y, Bi P, et al. Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy. Clin Transl Med. 2023;13:e1346.","journal-title":"Clin Transl Med"},{"key":"2477_CR466","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan M, Petitprez F, Becht E, Bougo\u00fcin A, Pupier G, Calvez A, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022;55:527-41.e5.","journal-title":"Immunity"},{"key":"2477_CR467","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-20-0949","volume":"9","author":"K Wennhold","year":"2021","unstructured":"Wennhold K, Thelen M, Lehmann J, Schran S, Preugszat E, Garcia-Marquez M, et al. CD86(+) antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses. Cancer Immunol Res. 2021;9:1098\u2013108.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2477_CR468","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02064-6","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen J, Tan Y, Sun F, Hou L, Zhang C, Ge T, et al. Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer. Genome Biol. 2020;21(1):152.","journal-title":"Genome Biol"},{"key":"2477_CR469","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1189\/jlb.5A0416-182R","volume":"101","author":"A Shimabukuro-Vornhagen","year":"2017","unstructured":"Shimabukuro-Vornhagen A, Garc\u00eda-M\u00e1rquez M, Fischer RN, Iltgen-Breburda J, Fiedler A, Wennhold K, et al. Antigen-presenting human B cells are expanded in inflammatory conditions. J Leukoc Biol. 2017;101:577\u201387.","journal-title":"J Leukoc Biol"},{"key":"2477_CR470","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.7150\/jca.37637","volume":"11","author":"J Jiang","year":"2020","unstructured":"Jiang J, Pan W, Xu Y, Ni C, Xue D, Chen Z, et al. Tumour-infiltrating immune cell-based subtyping and signature gene analysis in breast cancer based on gene expression profiles. J Cancer. 2020;11:1568\u201383.","journal-title":"J Cancer"},{"key":"2477_CR471","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221985120","volume":"120","author":"SJ Im","year":"2023","unstructured":"Im SJ, Obeng RC, Nasti TH, McManus D, Kamphorst AO, Gunisetty S, et al. Characteristics and anatomic location of PD-1(+)TCF1(+) stem-like CD8 T cells in chronic viral infection and cancer. Proc Natl Acad Sci U S A. 2023;120:e2221985120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR472","volume":"35","author":"J Zhang","year":"2021","unstructured":"Zhang J, Lyu T, Cao Y, Feng H. Role of TCF-1 in differentiation, exhaustion, and memory of CD8(+) T cells: A review. FASEB J. 2021;35:e21549.","journal-title":"FASEB J"},{"key":"2477_CR473","doi-asserted-by":"publisher","first-page":"eadh0380","DOI":"10.1126\/scitranslmed.adh0380","volume":"15","author":"Y Sato","year":"2023","unstructured":"Sato Y, Jain A, Ohtsuki S, Okuyama H, Sturmlechner I, Takashima Y, et al. Stem-like CD4(+) T cells in perivascular tertiary lymphoid structures sustain autoimmune vasculitis. Sci Transl Med. 2023;15:eadh0380.","journal-title":"Sci Transl Med"},{"key":"2477_CR474","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561\u20135.","journal-title":"Nature"},{"key":"2477_CR475","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1158\/2159-8290.CD-22-0201","volume":"12","author":"AG Goubet","year":"2022","unstructured":"Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, et al. Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov. 2022;12:2280\u2013307.","journal-title":"Cancer Discov"},{"key":"2477_CR476","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1158\/0008-5472.CAN-05-3619","volume":"66","author":"SC Yang","year":"2006","unstructured":"Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006;66:3205\u201313.","journal-title":"Cancer Res"},{"key":"2477_CR477","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, et al. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration. Clin Cancer Res. 2017;23:4556\u201368.","journal-title":"Clin Cancer Res"},{"key":"2477_CR478","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1322238","volume":"6","author":"AM Weinstein","year":"2017","unstructured":"Weinstein AM, Chen L, Brzana EA, Patil PR, Taylor JL, Fabian KL, et al. Tbet and IL-36\u03b3 cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology. 2017;6:e1322238.","journal-title":"Oncoimmunology"},{"key":"2477_CR479","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/cgt.2013.42","volume":"20","author":"L Chen","year":"2013","unstructured":"Chen L, Taylor JL, Sabins NC, Lowe DB, Qu Y, You Z, et al. Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther. 2013;20:469\u201377.","journal-title":"Cancer Gene Ther"},{"key":"2477_CR480","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01609","volume":"9","author":"G Zhu","year":"2018","unstructured":"Zhu G, Nemoto S, Mailloux AW, Perez-Villarroel P, Nakagawa R, Falahat R, et al. Induction of tertiary lymphoid structures with antitumor function by a lymph node-derived stromal cell line. Front Immunol. 2018;9:1609.","journal-title":"Front Immunol"},{"key":"2477_CR481","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203842","volume":"9","author":"JW Lee","year":"2022","unstructured":"Lee JW, Park BC, Jang NY, Lee S, Cho YK, Sharma P, et al. Inducing Ectopic T Cell Clusters Using Stromal Vascular Fraction Spheroid-Based Immunotherapy to Enhance Anti-Tumor Immunity. Adv Sci (Weinh). 2022;9:e2203842.","journal-title":"Adv Sci (Weinh)"},{"key":"2477_CR482","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jcmgh.2021.06.023","volume":"12","author":"FR Delvecchio","year":"2021","unstructured":"Delvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, et al. Pancreatic cancer chemotherapy is potentiated by induction of tertiary lymphoid structures in mice. Cell Mol Gastroenterol Hepatol. 2021;12:1543\u201365.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2477_CR483","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/path.5080","volume":"245","author":"B He","year":"2018","unstructured":"He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, et al. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. J Pathol. 2018;245:209\u201321.","journal-title":"J Pathol"},{"key":"2477_CR484","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14425-7","volume":"11","author":"Y Huang","year":"2020","unstructured":"Huang Y, Chen Y, Zhou S, Chen L, Wang J, Pei Y, et al. Dual-mechanism based CTLs infiltration enhancement initiated by nano-sapper potentiates immunotherapy against immune-excluded tumors. Nat Commun. 2020;11:622.","journal-title":"Nat Commun"},{"key":"2477_CR485","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002101","volume":"9","author":"JP Li","year":"2021","unstructured":"Li JP, Wu CY, Chen MY, Liu SX, Yan SM, Kang YF, et al. PD-1(+)CXCR5(-)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer. 2021;9:e002101.","journal-title":"J Immunother Cancer"},{"key":"2477_CR486","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01377-2","volume":"15","author":"M Spalato-Ceruso","year":"2022","unstructured":"Spalato-Ceruso M, Bouteiller F, Guegan JP, Toulmonde M, Bessede A, Kind M, et al. Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study. J Hematol Oncol. 2022;15:157.","journal-title":"J Hematol Oncol"},{"key":"2477_CR487","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1158\/0008-5472.CAN-06-0217","volume":"66","author":"M Lukashev","year":"2006","unstructured":"Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res. 2006;66:9617\u201324.","journal-title":"Cancer Res"},{"key":"2477_CR488","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001906","volume":"9","author":"M Chelvanambi","year":"2021","unstructured":"Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. Sting agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer. 2021;9:e001906.","journal-title":"J Immunother Cancer"},{"key":"2477_CR489","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","volume":"35","author":"L Wu","year":"2023","unstructured":"Wu L, Jin Y, Zhao X, Tang K, Zhao Y, Tong L, et al. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1. Cell Metab. 2023;35:1580-96.e9.","journal-title":"Cell Metab"},{"key":"2477_CR490","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2079182","volume":"11","author":"JB Zheng","year":"2022","unstructured":"Zheng JB, Wong CW, Liu J, Luo XJ, Zhou WY, Chen YX, et al. Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer. Oncoimmunology. 2022;11:2079182.","journal-title":"Oncoimmunology"},{"key":"2477_CR491","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.3_suppl.449","volume":"33","author":"RA Redman","year":"2015","unstructured":"Redman RA, Pohlmann PR, Kurman MR, Tapolsky G, Chesney JA. A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis. J Clin Oncol. 2015;33:TPS2606-TPS06.","journal-title":"J Clin Oncol"},{"key":"2477_CR492","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007349","volume":"11","author":"N Babl","year":"2023","unstructured":"Babl N, Decking SM, Voll F, Althammer M, Sala-Hojman A, Ferretti R, et al. MCT4 blockade increases the efficacy of immune checkpoint blockade. J Immunother Cancer. 2023;11:e007349.","journal-title":"J Immunother Cancer"},{"key":"2477_CR493","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111122","volume":"40","author":"J Gu","year":"2022","unstructured":"Gu J, Zhou J, Chen Q, Xu X, Gao J, Li X, et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-\u03b2 signaling in regulatory T cells. Cell Rep. 2022;40:111122.","journal-title":"Cell Rep"},{"key":"2477_CR494","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","volume":"29","author":"W Kelly","year":"2023","unstructured":"Kelly W, Diaz Duque AE, Michalek J, Konkel B, Caflisch L, Chen Y, et al. Phase II investigation of TVB-2640 (denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma. Clin Cancer Res. 2023;29:2419\u201325.","journal-title":"Clin Cancer Res"},{"key":"2477_CR495","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101234","volume":"4","author":"R Tang","year":"2023","unstructured":"Tang R, Xu J, Wang W, Meng Q, Shao C, Zhang Y, et al. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell Rep Med. 2023;4:101234.","journal-title":"Cell Rep Med"},{"key":"2477_CR496","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/1535-7163.MCT-20-0430","volume":"20","author":"S Varghese","year":"2021","unstructured":"Varghese S, Pramanik S, Williams LJ, Hodges HR, Hudgens CW, Fischer GM, et al. The glutaminase inhibitor CB-839 (telaglenastat) enhances the antimelanoma activity of T-cell-mediated immunotherapies. Mol Cancer Ther. 2021;20:500\u201311.","journal-title":"Mol Cancer Ther"},{"key":"2477_CR497","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","volume":"28","author":"CH Lee","year":"2022","unstructured":"Lee CH, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh JJ, et al. Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II entrada trial. Clin Cancer Res. 2022;28:3248\u201355.","journal-title":"Clin Cancer Res"},{"key":"2477_CR498","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-21-2972","volume":"28","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Tannir NM, Iliopoulos O, Lee RJ, Telli ML, Fan AC, et al. Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial. Clin Cancer Res. 2022;28:1540\u20138.","journal-title":"Clin Cancer Res"},{"key":"2477_CR499","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","volume":"8","author":"NM Tannir","year":"2022","unstructured":"Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, et al. Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial. JAMA Oncol. 2022;8:1411\u20138.","journal-title":"JAMA Oncol"},{"key":"2477_CR500","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140100","volume":"131","author":"DN Edwards","year":"2021","unstructured":"Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131:e140100.","journal-title":"J Clin Invest"},{"key":"2477_CR501","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jare.2023.12.013","volume":"65","author":"Y Vijayan","year":"2024","unstructured":"Vijayan Y, James S, Viswanathan A, Aparna JS, Bindu A, Namitha NN, et al. Targeting acid ceramidase enhances antitumor immune response in colorectal cancer. J Adv Res. 2024;65:73\u201387.","journal-title":"J Adv Res"},{"key":"2477_CR502","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20:1083\u201397.","journal-title":"Lancet Oncol"},{"key":"2477_CR503","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1038\/s41467-022-33285-x","volume":"13","author":"D Shi","year":"2022","unstructured":"Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 2022;13:5644.","journal-title":"Nat Commun"},{"key":"2477_CR504","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone T, Kar G, Spicer JD, Garc\u00eda-Campelo R, Weder W, Daniel DB, et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II neocoast platform trial. Cancer Discov. 2023;13:2394\u2013411.","journal-title":"Cancer Discov"},{"key":"2477_CR505","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:3383\u201393.","journal-title":"J Clin Oncol"},{"key":"2477_CR506","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-21-2742","volume":"28","author":"AA Chiappori","year":"2022","unstructured":"Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, et al. Phase I study of taminadenant (PBF509\/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab (PDR001), in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2022;28:2313\u201320.","journal-title":"Clin Cancer Res"},{"key":"2477_CR507","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","volume":"28","author":"EA Lim","year":"2022","unstructured":"Lim EA, Bendell JC, Falchook GS, Bauer TM, Drake CG, Choe JH, et al. Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors. Clin Cancer Res. 2022;28:4871\u201384.","journal-title":"Clin Cancer Res"},{"key":"2477_CR508","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"2477_CR509","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00490","volume":"7","author":"HY Chen","year":"2023","unstructured":"Chen HY, Zhao W, Na\u2019ara S, Gleber-Netto FO, Xie T, Ali S, et al. Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precis Oncol. 2023;7:e2200490.","journal-title":"JCO Precis Oncol"},{"key":"2477_CR510","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41586-023-06110-8","volume":"618","author":"J Zhu","year":"2023","unstructured":"Zhu J, Naulaerts S, Boudhan L, Martin M, Gatto L, Van den Eynde BJ. Tumour immune rejection triggered by activation of \u03b12-adrenergic receptors. Nature. 2023;618:607\u201315.","journal-title":"Nature"},{"key":"2477_CR511","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cmet.2022.10.012","volume":"34","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lin C, Liu Z, Sun Y, Chen M, Guo Y, et al. Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies. Cell Metab. 2022;34:1999-2017.e10.","journal-title":"Cell Metab"},{"key":"2477_CR512","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34242-4","volume":"13","author":"S Ravindranathan","year":"2022","unstructured":"Ravindranathan S, Passang T, Li JM, Wang S, Dhamsania R, Ware MB, et al. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Nat Commun. 2022;13:6418.","journal-title":"Nat Commun"},{"key":"2477_CR513","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1158\/1078-0432.CCR-22-3496","volume":"29","author":"C Perez-Pacheco","year":"2023","unstructured":"Perez-Pacheco C, Schmitd LB, Furgal A, Bellile EL, Liu M, Fattah A, et al. Increased nerve density adversely affects outcome in oral cancer. Clin Cancer Res. 2023;29:2501\u201312.","journal-title":"Clin Cancer Res"},{"key":"2477_CR514","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02241-8","volume":"10","author":"T Pu","year":"2025","unstructured":"Pu T, Sun J, Ren G, Li H. Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications. Signal Transduct Target Ther. 2025;10:176.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR515","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-024-00908-9","volume":"21","author":"SY Kwon","year":"2024","unstructured":"Kwon SY, Thi-Thu Ngo H, Son J, Hong Y, Min JJ. Exploiting bacteria for cancer immunotherapy. Nat Rev Clin Oncol. 2024;21:569\u201389.","journal-title":"Nat Rev Clin Oncol"},{"key":"2477_CR516","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01211-7","author":"A Elkrief","year":"2025","unstructured":"Elkrief A, Pidgeon R, Maleki Vareki S, Messaoudene M, Castagner B, Routy B. The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development. Nat Rev Drug Discov. 2025. https:\/\/doi.org\/10.1038\/s41573-025-01211-7.","journal-title":"Nat Rev Drug Discov"},{"key":"2477_CR517","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.immuni.2024.07.020","volume":"57","author":"L Zitvogel","year":"2024","unstructured":"Zitvogel L, Fidelle M, Kroemer G. Long-distance microbial mechanisms impacting cancer immunosurveillance. Immunity. 2024;57:2013\u201329.","journal-title":"Immunity"},{"key":"2477_CR518","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/CJI.0000000000000325","volume":"43","author":"TJ Gniadek","year":"2020","unstructured":"Gniadek TJ, Augustin L, Schottel J, Leonard A, Saltzman D, Greeno E, et al. A phase I, dose escalation, single dose trial of oral attenuated Salmonella typhimurium containing human IL-2 in patients with metastatic gastrointestinal cancers. J Immunother. 2020;43:217\u201321.","journal-title":"J Immunother"},{"key":"2477_CR519","doi-asserted-by":"publisher","DOI":"10.1093\/lifemeta\/load032","volume":"2","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Wu J, Ding Y, Pang Y, Jiang C. Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions. Life Metab. 2023;2:load032.","journal-title":"Life Metab"},{"key":"2477_CR520","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079\u201384.","journal-title":"Science"},{"key":"2477_CR521","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137.","journal-title":"Science"},{"key":"2477_CR522","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97\u2013103.","journal-title":"Science"},{"key":"2477_CR523","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104\u20138.","journal-title":"Science"},{"key":"2477_CR524","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28:315\u201324.","journal-title":"Nat Med"},{"key":"2477_CR525","doi-asserted-by":"publisher","first-page":"eabo2296","DOI":"10.1126\/science.abo2296","volume":"380","author":"M Fidelle","year":"2023","unstructured":"Fidelle M, Rauber C, Alves CSC, Tian AL, Lahmar I, de La Varende AM, et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science. 2023;380:eabo2296.","journal-title":"Science"},{"key":"2477_CR526","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595\u2013602.","journal-title":"Science"},{"key":"2477_CR527","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602\u20139.","journal-title":"Science"},{"key":"2477_CR528","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B, Lenehan JG, Miller WH Jr., Jamal R, Messaoudene M, Daisley BA, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023;29:2121\u201332.","journal-title":"Nat Med"},{"key":"2477_CR529","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.annonc.2023.02.011","volume":"34","author":"A Spreafico","year":"2023","unstructured":"Spreafico A, Heirali AA, Araujo DV, Tan TJ, Oliva M, Schneeberger PHH, et al. First-in-class microbial ecosystem therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann Oncol. 2023;34:520\u201330.","journal-title":"Ann Oncol"},{"key":"2477_CR530","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022;28:704\u201312.","journal-title":"Nat Med"},{"key":"2477_CR531","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-022-04985-7","volume":"608","author":"M Bae","year":"2022","unstructured":"Bae M, Cassilly CD, Liu X, Park SM, Tusi BK, Chen X, et al. Akkermansia muciniphila phospholipid induces homeostatic immune responses. Nature. 2022;608:168\u201373.","journal-title":"Nature"},{"key":"2477_CR532","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020;369:1481\u20139.","journal-title":"Science"},{"key":"2477_CR533","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374:1632\u201340.","journal-title":"Science"},{"key":"2477_CR534","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41551-021-00749-2","volume":"5","author":"K Han","year":"2021","unstructured":"Han K, Nam J, Xu J, Sun X, Huang X, Animasahun O, et al. Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel. Nat Biomed Eng. 2021;5:1377\u201388.","journal-title":"Nat Biomed Eng"},{"key":"2477_CR535","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/2159-8290.CD-21-0808","volume":"12","author":"M Messaoudene","year":"2022","unstructured":"Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, et al. A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer Discov. 2022;12:1070\u201387.","journal-title":"Cancer Discov"},{"key":"2477_CR536","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.immuni.2022.09.014","volume":"55","author":"D Denk","year":"2022","unstructured":"Denk D, Petrocelli V, Conche C, Drachsler M, Ziegler PK, Braun A, et al. Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. Immunity. 2022;55:2059-73.e8.","journal-title":"Immunity"},{"key":"2477_CR537","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","volume":"187","author":"K Newton","year":"2024","unstructured":"Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187:235\u201356.","journal-title":"Cell"},{"key":"2477_CR538","doi-asserted-by":"publisher","first-page":"20167","DOI":"10.1021\/acsnano.4c03034","volume":"18","author":"Y-Y Wang","year":"2024","unstructured":"Wang Y-Y, Wang J, Wang S, Yang Q-C, Song A, Zhang M-J, et al. Dual-responsive epigenetic inhibitor nanoprodrug combined with oncolytic virus synergistically boost cancer immunotherapy by igniting Gasdermin E-mediated pyroptosis. ACS Nano. 2024;18:20167\u201380.","journal-title":"ACS Nano"},{"key":"2477_CR539","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s43018-024-00879-x","volume":"6","author":"JM Ressler","year":"2025","unstructured":"Ressler JM, Plaschka M, Silmbrod R, Bachmayr V, Shaw LE, Silly T, et al. Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial). Nat Cancer. 2025;6:51\u201366.","journal-title":"Nat Cancer"},{"key":"2477_CR540","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41121-z","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Song A, Yang QC, Li SJ, Wang S, Wan SC, et al. Integration of AIEgens into covalent organic frameworks for pyroptosis and ferroptosis primed cancer immunotherapy. Nat Commun. 2023;14:5355.","journal-title":"Nat Commun"},{"key":"2477_CR541","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoto.2013.3387","volume":"139","author":"NR Rigual","year":"2013","unstructured":"Rigual NR, Shafirstein G, Frustino J, Seshadri M, Cooper M, Wilding G, et al. Adjuvant intraoperative photodynamic therapy in head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2013;139:706\u201311.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2477_CR542","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202403118","volume":"34","author":"T Tian","year":"2024","unstructured":"Tian T, Wang J, Wang W, Wu H, Li Q, Wang F, et al. Colloidal hydrogel for sensitizing microwave ablation-induced in situ tumor vaccination and modulating innate and adaptive immunotherapy. Adv Funct Mater. 2024;34:2403118.","journal-title":"Adv Funct Mater"},{"key":"2477_CR543","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202135","volume":"12","author":"SC Wan","year":"2023","unstructured":"Wan SC, Ye MJ, Yang QC, Zhang T, Zhang MJ, Ma XB, et al. Diselenide-Based Dual-Responsive Prodrug as Pyroptosis Inducer Potentiates Cancer Immunotherapy. Adv Healthcare Mater. 2023;12:e2202135.","journal-title":"Adv Healthcare Mater"},{"key":"2477_CR544","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-20-3435","volume":"27","author":"J Spicer","year":"2021","unstructured":"Spicer J, Marabelle A, Baurain JF, Jebsen NL, J\u00f8ssang DE, Awada A, et al. Safety, antitumor activity, and T-cell responses in a dose-ranging phase I trial of the oncolytic peptide LTX-315 in patients with solid tumors. Clin Cancer Res. 2021;27:2755\u201363.","journal-title":"Clin Cancer Res"},{"key":"2477_CR545","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02183-9","volume":"23","author":"H Wang","year":"2024","unstructured":"Wang H, Wang T, Yan S, Tang J, Zhang Y, Wang L, et al. Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication. Mol Cancer. 2024;23:268.","journal-title":"Mol Cancer"},{"key":"2477_CR546","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-020-2079-1","volume":"579","author":"Q Wang","year":"2020","unstructured":"Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579:421\u20136.","journal-title":"Nature"},{"key":"2477_CR547","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105420","volume":"109","author":"YR Zhou","year":"2024","unstructured":"Zhou YR, Dang JJ, Yang QC, Sun ZJ. The regulation of pyroptosis by post-translational modifications: molecular mechanisms and therapeutic targets. EBioMedicine. 2024;109:105420.","journal-title":"EBioMedicine"},{"key":"2477_CR548","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35917-2","volume":"14","author":"J Lin","year":"2023","unstructured":"Lin J, Sun S, Zhao K, Gao F, Wang R, Li Q, et al. Oncolytic parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. Nat Commun. 2023;14:224.","journal-title":"Nat Commun"},{"key":"2477_CR549","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42:513\u201334.","journal-title":"Cancer Cell"},{"key":"2477_CR550","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/procel\/pwae003","volume":"15","author":"C Mao","year":"2024","unstructured":"Mao C, Wang M, Zhuang L, Gan B. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond. Protein Cell. 2024;15:642\u201360.","journal-title":"Protein Cell"},{"key":"2477_CR551","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.immuni.2024.03.019","volume":"57","author":"HN Bell","year":"2024","unstructured":"Bell HN, Stockwell BR, Zou W. Ironing out the role of ferroptosis in immunity. Immunity. 2024;57:941\u201356.","journal-title":"Immunity"},{"key":"2477_CR552","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01772-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Chen C, Zhao C, Li T, Ma L, Jiang J, et al. Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer. Signal Transduct Target Ther. 2024;9:64.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR553","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1158\/0008-5472.CAN-24-1941","volume":"85","author":"W Zeng","year":"2025","unstructured":"Zeng W, Zhang R, Huang P, Chen M, Chen H, Zeng X, et al. Ferroptotic neutrophils induce immunosuppression and chemoresistance in breast cancer. Cancer Res. 2025;85:477\u201396.","journal-title":"Cancer Res"},{"key":"2477_CR554","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.immuni.2024.08.003","volume":"57","author":"Y Ping","year":"2024","unstructured":"Ping Y, Shan J, Qin H, Li F, Qu J, Guo R, et al. PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8(+) T cell ferroptosis. Immunity. 2024;57:2122-39.e9.","journal-title":"Immunity"},{"key":"2477_CR555","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254\u201361.","journal-title":"Science"},{"key":"2477_CR556","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41418-024-01341-2","volume":"31","author":"YT Liu","year":"2024","unstructured":"Liu YT, Chen L, Li SJ, Wang WY, Wang YY, Yang QC, et al. Dysregulated Wnt\/\u03b2-catenin signaling confers resistance to cuproptosis in cancer cells. Cell Death Differ. 2024;31:1452\u201366.","journal-title":"Cell Death Differ"},{"key":"2477_CR557","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122512","volume":"307","author":"X Yu","year":"2024","unstructured":"Yu X, Li B, Yan J, Li W, Tian H, Wang G, et al. Cuproptotic nanoinducer-driven proteotoxic stress potentiates cancer immunotherapy by activating the mtDNA-cGAS-STING signaling. Biomaterials. 2024;307:122512.","journal-title":"Biomaterials"},{"key":"2477_CR558","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309984","volume":"11","author":"X Lu","year":"2024","unstructured":"Lu X, Chen X, Lin C, Yi Y, Zhao S, Zhu B, et al. Elesclomol loaded copper oxide nanoplatform triggers cuproptosis to enhance antitumor immunotherapy. Adv Sci. 2024;11:e2309984.","journal-title":"Adv Sci"},{"key":"2477_CR559","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ygyno.2018.10.001","volume":"151","author":"BJ Monk","year":"2018","unstructured":"Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, et al. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: an NRG oncology\/gynecologic oncology group study. Gynecol Oncol. 2018;151:422\u20137.","journal-title":"Gynecol Oncol"},{"key":"2477_CR560","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54469-7","volume":"15","author":"M Guan","year":"2024","unstructured":"Guan M, Cheng K, Xie XT, Li Y, Ma MW, Zhang B, et al. Regulating copper homeostasis of tumor cells to promote cuproptosis for enhancing breast cancer immunotherapy. Nat Commun. 2024;15:10060.","journal-title":"Nat Commun"},{"key":"2477_CR561","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202411609","volume":"63","author":"S Wang","year":"2024","unstructured":"Wang S, Liu Y, Su M, Wang Y, Wang W, Wang W, et al. Near-Infrared Activatable Copper Nanoplatforms Synergize with the 5-Azacytidine Prodrug to Potentiate Cuproptosis. Angew Chem Int Ed Engl. 2024;63:e202411609.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2477_CR562","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202419649","volume":"64","author":"G Hou","year":"2025","unstructured":"Hou G, Chen Y, Lei H, Lu S, Cheng L. Nanomaterials-induced PANoptosis: a promising anti-tumor strategy. Angew Chem Int Ed Engl. 2025;64:e202419649.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2477_CR563","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1016\/j.cell.2024.05.034","volume":"187","author":"B Sundaram","year":"2024","unstructured":"Sundaram B, Pandian N, Kim HJ, Abdelaal HM, Mall R, Indari O, et al. NLRC5 senses NAD(+) depletion, forming a PANoptosome and driving PANoptosis and inflammation. Cell. 2024;187:4061-77.e17.","journal-title":"Cell"},{"key":"2477_CR564","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.molmed.2023.10.001","volume":"30","author":"A Pandeya","year":"2024","unstructured":"Pandeya A, Kanneganti TD. Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes. Trends Mol Med. 2024;30:74\u201388.","journal-title":"Trends Mol Med"},{"key":"2477_CR565","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48032-7","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S, Song A, Xie J, Wang YY, Wang WD, Zhang MJ, et al. Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity. Nat Commun. 2024;15:3669.","journal-title":"Nat Commun"},{"key":"2477_CR566","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41556-023-01091-2","volume":"25","author":"X Liu","year":"2023","unstructured":"Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol. 2023;25:404\u201314.","journal-title":"Nat Cell Biol"},{"key":"2477_CR567","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202410957","volume":"37","author":"XK Jin","year":"2025","unstructured":"Jin XK, Zhang SK, Zhang SM, Liang JL, Yan X, Lin YT, et al. Disrupting Intracellular Homeostasis by Copper-Based Nanoinducer with Multiple Enzyme-Mimicking Activities to Induce Disulfidptosis-Enhanced Pyroptosis for Tumor Immunotherapy. Adv Mater. 2025;37:e2410957.","journal-title":"Adv Mater"},{"key":"2477_CR568","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111205","volume":"40","author":"M Gros","year":"2022","unstructured":"Gros M, Segura E, Rookhuizen DC, Baudon B, Heurtebise-Chr\u00e9tien S, Burgdorf N, et al. Endocytic membrane repair by ESCRT-III controls antigen export to the cytosol during antigen cross-presentation. Cell Rep. 2022;40:111205.","journal-title":"Cell Rep"},{"key":"2477_CR569","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.trsl.2020.11.005","volume":"230","author":"E Tomasich","year":"2021","unstructured":"Tomasich E, Topakian T, Heller G, Udovica S, Krainer M, Marhold M. Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer. Transl Res. 2021;230:21\u201333.","journal-title":"Transl Res"},{"key":"2477_CR570","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.celrep.2018.06.066","volume":"24","author":"J Monypenny","year":"2018","unstructured":"Monypenny J, Milewicz H, Flores-Borja F, Weitsman G, Cheung A, Chowdhury R, et al. ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation. Cell Rep. 2018;24:630\u201341.","journal-title":"Cell Rep"},{"key":"2477_CR571","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","volume":"22","author":"SW Linderman","year":"2025","unstructured":"Linderman SW, DeRidder L, Sanjurjo L, Foote MB, Alonso MJ, Kirtane AR, et al. Enhancing immunotherapy with tumour-responsive nanomaterials. Nat Rev Clin Oncol. 2025;22:262\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"2477_CR572","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1039\/D4CS00679H","volume":"54","author":"M Ma","year":"2025","unstructured":"Ma M, Zhang Y, Pu K, Tang W. Nanomaterial-enabled metabolic reprogramming strategies for boosting antitumor immunity. Chem Soc Rev. 2025;54:653\u2013714.","journal-title":"Chem Soc Rev"},{"key":"2477_CR573","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1039\/C8CS00618K","volume":"48","author":"Y Liu","year":"2019","unstructured":"Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev. 2019;48:2053\u2013108.","journal-title":"Chem Soc Rev"},{"key":"2477_CR574","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8:293.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR575","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103444","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lin Y, Lin Z, Wei Q, Qian J, Ruan R, et al. Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy. Adv Sci (Weinh). 2022;9:e2103444.","journal-title":"Adv Sci (Weinh)"},{"key":"2477_CR576","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1039\/D0CS00152J","volume":"50","author":"GF Luo","year":"2021","unstructured":"Luo GF, Chen WH, Zeng X, Zhang XZ. Cell primitive-based biomimetic functional materials for enhanced cancer therapy. Chem Soc Rev. 2021;50:945\u201385.","journal-title":"Chem Soc Rev"},{"key":"2477_CR577","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.5c00069","author":"S Duan","year":"2025","unstructured":"Duan S, Hua M, Zhang CW, Hong W, Yan Y, Jazzar A, et al. Noncovalent aggregation for diverse properties in hydrogels: a comprehensive review. Chem Rev. 2025. https:\/\/doi.org\/10.1021\/acs.chemrev.5c00069.","journal-title":"Chem Rev"},{"key":"2477_CR578","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01852-x","volume":"9","author":"P Lu","year":"2024","unstructured":"Lu P, Ruan D, Huang M, Tian M, Zhu K, Gan Z, et al. Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions. Signal Transduct Target Ther. 2024;9:166.","journal-title":"Signal Transduct Target Ther"},{"key":"2477_CR579","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202502455:e2502455","author":"D Miao","year":"2025","unstructured":"Miao D, Luo R, Li Y, Qin X, Wang Y, Zhang Y, et al. Injectable Functional Porous Carbon-Loaded Hydrogel with Long-Term Retention and Synergistic Anti-Tumor Properties for Tumor Therapy. Adv Mater. 2025. https:\/\/doi.org\/10.1002\/adma.202502455:e2502455.","journal-title":"Adv Mater"},{"key":"2477_CR580","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201900927","volume":"31","author":"Z Meng","year":"2019","unstructured":"Meng Z, Zhou X, Xu J, Han X, Dong Z, Wang H, et al. Light-Triggered In Situ Gelation to Enable Robust Photodynamic-Immunotherapy by Repeated Stimulations. Adv Mater. 2019;31:e1900927.","journal-title":"Adv Mater"},{"key":"2477_CR581","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41467-025-56137-w","volume":"16","author":"J Ding","year":"2025","unstructured":"Ding J, Wang T, Lin Z, Li Z, Yang J, Li F, et al. Chiral polypeptide hydrogels regulating local immune microenvironment and anti-tumor immune response. Nat Commun. 2025;16:1222.","journal-title":"Nat Commun"},{"key":"2477_CR582","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121506","volume":"284","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Gong Y, Chen X, Zhang Q, Zhang X, He Y, et al. Injectable adhesive hemostatic gel with tumor acidity neutralizer and neutrophil extracellular traps lyase for enhancing adoptive NK cell therapy prevents post-resection recurrence of hepatocellular carcinoma. Biomaterials. 2022;284:121506.","journal-title":"Biomaterials"},{"key":"2477_CR583","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32160-z","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Tian S, Huang L, Li Y, Lu Y, Li H, et al. Reactive oxygen species-responsive and raman-traceable hydrogel combining photodynamic and immune therapy for postsurgical cancer treatment. Nat Commun. 2022;13:4553.","journal-title":"Nat Commun"},{"key":"2477_CR584","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn8264","volume":"8","author":"AK Grosskopf","year":"2022","unstructured":"Grosskopf AK, Labanieh L, Klysz DD, Roth GA, Xu P, Adebowale O, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci Adv. 2022;8:eabn8264.","journal-title":"Sci Adv"},{"key":"2477_CR585","doi-asserted-by":"publisher","first-page":"23223","DOI":"10.1021\/acsnano.3c06019","volume":"17","author":"D Wei","year":"2023","unstructured":"Wei D, Sun Y, Zhu H, Fu Q. Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano. 2023;17:23223\u201361.","journal-title":"ACS Nano"},{"key":"2477_CR586","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202419033","volume":"37","author":"J Yang","year":"2025","unstructured":"Yang J, Su T, Wang Q, Shi R, Ding J, Chen X. Glucose Metabolism-Targeted Poly(amino acid) Nanoformulation of Oxaliplatin(IV)-Aspirin Prodrug for Enhanced Chemo-Immunotherapy. Adv Mater. 2025;37:e2419033.","journal-title":"Adv Mater"},{"key":"2477_CR587","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201902960","volume":"31","author":"B Feng","year":"2019","unstructured":"Feng B, Hou B, Xu Z, Saeed M, Yu H, Li Y. Self-Amplified Drug Delivery with Light-Inducible Nanocargoes to Enhance Cancer Immunotherapy. Adv Mater. 2019;31:e1902960.","journal-title":"Adv Mater"},{"key":"2477_CR588","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201803001","volume":"30","author":"B Feng","year":"2018","unstructured":"Feng B, Zhou F, Hou B, Wang D, Wang T, Fu Y, et al. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment. Adv Mater. 2018;30:e1803001.","journal-title":"Adv Mater"},{"key":"2477_CR589","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202201486","volume":"61","author":"D Wei","year":"2022","unstructured":"Wei D, Huang Y, Wang B, Ma L, Karges J, Xiao H. Photo-Reduction with NIR Light of Nucleus-Targeting Pt(IV) Nanoparticles for Combined Tumor-Targeted Chemotherapy and Photodynamic Immunotherapy. Angew Chem Int Ed Engl. 2022;61:e202201486.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2477_CR590","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202413210","volume":"37","author":"EL Yang","year":"2025","unstructured":"Yang EL, Wang WY, Liu YQ, Yi H, Lei A, Sun ZJ. Tumor-targeted catalytic immunotherapy. Adv Mater. 2025;37:e2413210.","journal-title":"Adv Mater"},{"key":"2477_CR591","doi-asserted-by":"publisher","first-page":"2302606","DOI":"10.1002\/adhm.202302606","volume":"13","author":"N Zhang","year":"2024","unstructured":"Zhang N, Zeng W, Xu Y, Li R, Wang M, Liu Y, et al. Pyroptosis Induction with Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with PD-L1 Blockade Boosts Efficacy against Liver Cancer. Adv Healthcare Mater. 2024;13:2302606.","journal-title":"Adv Healthcare Mater"},{"key":"2477_CR592","doi-asserted-by":"publisher","first-page":"11862","DOI":"10.1021\/acsnano.2c00969","volume":"16","author":"Z Sun","year":"2022","unstructured":"Sun Z, Wang Z, Wang T, Wang J, Zhang H, Li Z, et al. Biodegradable MnO-based nanoparticles with engineering surface for tumor therapy: simultaneous Fenton-like ion delivery and immune activation. ACS Nano. 2022;16:11862\u201375.","journal-title":"ACS Nano"},{"key":"2477_CR593","doi-asserted-by":"publisher","first-page":"295","DOI":"10.7150\/thno.80687","volume":"13","author":"J Yang","year":"2023","unstructured":"Yang J, Dai D, Zhang X, Teng L, Ma L, Yang Y-W. Multifunctional metal-organic framework (MOF)-based nanoplatforms for cancer therapy: from single to combination therapy. Theranostics. 2023;13:295\u2013323.","journal-title":"Theranostics"},{"key":"2477_CR594","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202306748","volume":"35","author":"R Wang","year":"2023","unstructured":"Wang R, Qiu M, Zhang L, Sui M, Xiao L, Yu Q, et al. Augmenting Immunotherapy via Bioinspired MOF-Based ROS Homeostasis Disruptor with Nanozyme-Cascade Reaction. Adv Mater. 2023;35:e2306748.","journal-title":"Adv Mater"},{"key":"2477_CR595","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206779","volume":"10","author":"T Li","year":"2023","unstructured":"Li T, Gao M, Wu Z, Yang J, Mo B, Yu S, et al. Tantalum-Zirconium Co-Doped Metal-Organic Frameworks Sequentially Sensitize Radio-Radiodynamic-Immunotherapy for Metastatic Osteosarcoma. Adv Sci (Weinh). 2023;10:e2206779.","journal-title":"Adv Sci (Weinh)"},{"key":"2477_CR596","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1039\/D3CS00673E","volume":"53","author":"X Wu","year":"2024","unstructured":"Wu X, Li Y, Wen M, Xie Y, Zeng K, Liu YN, et al. Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications. Chem Soc Rev. 2024;53:2643\u201392.","journal-title":"Chem Soc Rev"},{"key":"2477_CR597","doi-asserted-by":"publisher","first-page":"2312919","DOI":"10.1002\/adfm.202312919","volume":"34","author":"Z Xiong","year":"2024","unstructured":"Xiong Z, Yang M, Liu P, Tang Z, Yang Y, Zhan M, et al. Designing Bimetallic Metal-Organic Framework-Based Heterojunction Radiosensitizer for Enhanced Radiodynamic Therapy and Immunotherapy. Adv Funct Mater. 2024;34:2312919.","journal-title":"Adv Funct Mater"},{"key":"2477_CR598","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202313890","volume":"34","author":"B Zhang","year":"2024","unstructured":"Zhang B, Zhang L, Wang W, Yang E, Song A, Xiong D, et al. Single-cell RNA-sequencing-aided covalent organic frameworks-based microneedle design targeting phototherapy resistant tumor cell. Adv Funct Mater. 2024;34:2313890.","journal-title":"Adv Funct Mater"},{"key":"2477_CR599","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122610","volume":"309","author":"D Liu","year":"2024","unstructured":"Liu D, Liang M, Tao Y, Liu H, Liu Q, Bing W, et al. Hypoxia-accelerating pyroptosis nanoinducers for promoting image-guided cancer immunotherapy. Biomaterials. 2024;309:122610.","journal-title":"Biomaterials"},{"key":"2477_CR600","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70025","author":"X Kong","year":"2025","unstructured":"Kong X, Xie X, Wu J, Wang X, Zhang W, Wang S, et al. Combating cancer immunotherapy resistance: a nano-medicine perspective. Cancer Commun. 2025. https:\/\/doi.org\/10.1002\/cac2.70025.","journal-title":"Cancer Commun"},{"key":"2477_CR601","doi-asserted-by":"publisher","first-page":"32689","DOI":"10.1021\/jacs.4c12166","volume":"146","author":"J Gan","year":"2024","unstructured":"Gan J, Lei J, Li Y, Lu M, Yu X, Yu G. Manganese oxide-incorporated hybrid lipid nanoparticles amplify the potency of mRNA vaccine via oxygen generation and STING activation. J Am Chem Soc. 2024;146:32689\u2013700.","journal-title":"J Am Chem Soc"},{"key":"2477_CR602","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nnano.2016.168","volume":"11","author":"S Zanganeh","year":"2016","unstructured":"Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11:986\u201394.","journal-title":"Nat Nanotechnol"},{"key":"2477_CR603","doi-asserted-by":"publisher","DOI":"10.3390\/ma13204644","author":"N Ajinkya","year":"2020","unstructured":"Ajinkya N, Yu X, Kaithal P, Luo H, Somani P, Ramakrishna S. Magnetic iron oxide nanoparticle (IONP) synthesis to applications: present and future. Materials. 2020. https:\/\/doi.org\/10.3390\/ma13204644.","journal-title":"Materials"},{"key":"2477_CR604","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.drudis.2021.01.030","volume":"26","author":"XY Liu","year":"2021","unstructured":"Liu XY, Wang JQ, Ashby CR Jr., Zeng L, Fan YF, Chen ZS. Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discov Today. 2021;26:1284\u201392.","journal-title":"Drug Discov Today"},{"key":"2477_CR605","doi-asserted-by":"publisher","first-page":"24144","DOI":"10.1021\/acsami.2c03839","volume":"14","author":"WP Su","year":"2022","unstructured":"Su WP, Chang LC, Song WH, Yang LX, Wang LC, Chia ZC, et al. Polyaniline-based glyco-condensation on Au nanoparticles enhances immunotherapy in lung cancer. ACS Appl Mater Interfaces. 2022;14:24144\u201359.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2477_CR606","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","volume":"20","author":"S Bonvalot","year":"2019","unstructured":"Bonvalot S, Rutkowski PL, Thariat J, Carr\u00e8re S, Ducassou A, Sunyach MP, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In.Sarc): a multicentre, phase 2\u20133, randomised, controlled trial. Lancet Oncol. 2019;20:1148\u201359.","journal-title":"Lancet Oncol"},{"key":"2477_CR607","doi-asserted-by":"publisher","first-page":"23941","DOI":"10.1021\/acsnano.3c10588","volume":"18","author":"H Zu","year":"2024","unstructured":"Zu H, Wu Y, Meng H, Cheng X, Wang Y, Zhang LW. Tumor metabolism aiming Cu(2\u2013x)S nanoagents mediate photothermal-derived cuproptosis and immune activation. ACS Nano. 2024;18:23941\u201357.","journal-title":"ACS Nano"},{"key":"2477_CR608","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202500337","volume":"37","author":"B Liu","year":"2025","unstructured":"Liu B, Chen X, Zhu Y, Chen H, Tan J, Yang Z, et al. One-Step Symbiosis of Bimetallic Peroxides Nanoparticles to Induce Ferroptosis\/Cuproptosis and Activate cGAS-STING Pathway for Enhanced Tumor Immunotherapy. Adv Mater. 2025;37:e2500337.","journal-title":"Adv Mater"},{"key":"2477_CR609","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201706356","volume":"30","author":"KJ McHugh","year":"2018","unstructured":"McHugh KJ, Jing L, Behrens AM, Jayawardena S, Tang W, Gao M, et al. Biocompatible Semiconductor Quantum Dots as Cancer Imaging Agents. Adv Mater. 2018;30:e1706356.","journal-title":"Adv Mater"},{"key":"2477_CR610","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27485-0","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Wang M, Huang B, Zhu S-W, Zhou J-J, Chen D-R, et al. Theranostic near-infrared-IIb emitting nanoprobes for promoting immunogenic radiotherapy and abscopal effects against cancer metastasis. Nat Commun. 2021;12:7149.","journal-title":"Nat Commun"},{"key":"2477_CR611","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biomaterials.2016.03.003","volume":"90","author":"Y Lu","year":"2016","unstructured":"Lu Y, Xu S, Chen H, He M, Deng Y, Cao Z, et al. CdSe\/ZnS quantum dots induce hepatocyte pyroptosis and liver inflammation via NLRP3 inflammasome activation. Biomaterials. 2016;90:27\u201339.","journal-title":"Biomaterials"},{"key":"2477_CR612","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01943-y","author":"D Wang","year":"2025","unstructured":"Wang D, Ji L, Li Y, Xu M, Wang H, Brovelli S, et al. Iron\u2013silver-modified quantum dots act as efficient catalysts in anti-cancer multitherapy through controlled, ultrasound-induced oxidation. Nat Nanotechnol. 2025. https:\/\/doi.org\/10.1038\/s41565-025-01943-y.","journal-title":"Nat Nanotechnol"},{"key":"2477_CR613","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01713-1","volume":"4","author":"L Qi","year":"2021","unstructured":"Qi L, Pan T, Ou L, Ye Z, Yu C, Bao B, et al. Biocompatible nucleus-targeted graphene quantum dots for selective killing of cancer cells via DNA damage. Commun Biol. 2021;4:214.","journal-title":"Commun Biol"},{"key":"2477_CR614","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125336","volume":"672","author":"R Samanta","year":"2025","unstructured":"Samanta R, Haldar N, Pamecha A, Gajbhiye V. Cell membrane-camouflaged nanocarriers: a cutting-edge biomimetic technology to develop cancer immunotherapy. Int J Pharm. 2025;672:125336.","journal-title":"Int J Pharm"},{"key":"2477_CR615","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202102712","volume":"11","author":"Y Lu","year":"2022","unstructured":"Lu Y, Gong Y, Zhu X, Dong X, Zhu D, Ma G. Design of Light-Activated Nanoplatform through Boosting \u201cEat Me\u201d Signals for Improved CD47-Blocking Immunotherapy. Adv Healthcare Mater. 2022;11:e2102712.","journal-title":"Adv Healthcare Mater"},{"key":"2477_CR616","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02368-w","volume":"24","author":"KM Abdullah","year":"2025","unstructured":"Abdullah KM, Sharma G, Singh AP, Siddiqui JA. Nanomedicine in cancer therapeutics: current perspectives from bench to bedside. Mol Cancer. 2025;24:169.","journal-title":"Mol Cancer"},{"key":"2477_CR617","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.ijbiomac.2022.11.152","volume":"225","author":"M Lin","year":"2023","unstructured":"Lin M, Li Y, Long H, Lin Y, Zhang Z, Zhan F, et al. Cell membrane-camouflaged DOX-loaded \u03b2-glucan nanoparticles for highly efficient cancer immunochemotherapy. Int J Biol Macromol. 2023;225:873\u201385.","journal-title":"Int J Biol Macromol"},{"key":"2477_CR618","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202001704","volume":"16","author":"Q Jiang","year":"2020","unstructured":"Jiang Q, Wang K, Zhang X, Ouyang B, Liu H, Pang Z, et al. Platelet Membrane-Camouflaged Magnetic Nanoparticles for Ferroptosis-Enhanced Cancer Immunotherapy. Small. 2020;16:e2001704.","journal-title":"Small"},{"key":"2477_CR619","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20230171","volume":"4","author":"M Yang","year":"2024","unstructured":"Yang M, Zhou J, Lu L, Deng D, Huang J, Tang Z, et al. Tumor cell membrane-based vaccines: a potential boost for cancer immunotherapy. Exploration. 2024;4:20230171.","journal-title":"Exploration"},{"key":"2477_CR620","first-page":"299","volume":"21","author":"Z Li","year":"2023","unstructured":"Li Z, Cai H, Li Z, Ren L, Ma X, Zhu H, et al. A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody. Bioact Mater. 2023;21:299\u2013312.","journal-title":"Bioact Mater"},{"key":"2477_CR621","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202004853","volume":"32","author":"L Rao","year":"2020","unstructured":"Rao L, Zhao SK, Wen C, Tian R, Lin L, Cai B, et al. Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles. Adv Mater. 2020;32:e2004853.","journal-title":"Adv Mater"},{"key":"2477_CR622","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202300964","volume":"35","author":"Q Tang","year":"2023","unstructured":"Tang Q, Sun S, Wang P, Sun L, Wang Y, Zhang L, et al. Genetically Engineering Cell Membrane-Coated BTO Nanoparticles for MMP2-Activated Piezocatalysis-Immunotherapy. Adv Mater. 2023;35:e2300964.","journal-title":"Adv Mater"},{"key":"2477_CR623","doi-asserted-by":"publisher","first-page":"59117","DOI":"10.1021\/acsami.3c12560","volume":"15","author":"S Zhang","year":"2023","unstructured":"Zhang S, Chen W, Zhou Y, Zheng X, Fu Y, Liu H, et al. Intelligent nanoplatform integrating macrophage and cancer cell membrane for synergistic chemodynamic\/immunotherapy\/photothermal therapy of breast cancer. ACS Appl Mater Interfaces. 2023;15:59117\u201333.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2477_CR624","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c10568","author":"C Zhang","year":"2024","unstructured":"Zhang C, Tang S, Wang M, Li L, Li J, Wang D, et al. \u201cTriple-Punch\u201d Strategy Exosome-Mimetic Nanovesicles for Triple Negative Breast Cancer Therapy. ACS Nano. 2024. https:\/\/doi.org\/10.1021\/acsnano.3c10568.","journal-title":"ACS Nano"},{"key":"2477_CR625","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216151","volume":"561","author":"J Garc\u00eda-Fern\u00e1ndez","year":"2023","unstructured":"Garc\u00eda-Fern\u00e1ndez J, Fuente FM. Exosome-like systems: nanotechnology to overcome challenges for targeted cancer therapies. Cancer Lett. 2023;561:216151.","journal-title":"Cancer Lett"},{"key":"2477_CR626","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/anie.201912524","volume":"59","author":"W Nie","year":"2020","unstructured":"Nie W, Wu G, Zhang J, Huang LL, Ding J, Jiang A, et al. Responsive Exosome Nano-bioconjugates for Synergistic Cancer Therapy. Angew Chem Int Ed Engl. 2020;59:2018\u201322.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2477_CR627","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.biomaterials.2017.01.004","volume":"121","author":"E Koh","year":"2017","unstructured":"Koh E, Lee EJ, Nam GH, Hong Y, Cho E, Yang Y, et al. Exosome-SIRP\u03b1, a CD47 blockade increases cancer cell phagocytosis. Biomaterials. 2017;121:121\u20139.","journal-title":"Biomaterials"},{"key":"2477_CR628","doi-asserted-by":"publisher","first-page":"15598","DOI":"10.1039\/C7NR04425A","volume":"9","author":"J Wang","year":"2017","unstructured":"Wang J, Li W, Lu Z, Zhang L, Hu Y, Li Q, et al. The use of RGD-engineered exosomes for enhanced targeting ability and synergistic therapy toward angiogenesis. Nanoscale. 2017;9:15598\u2013605.","journal-title":"Nanoscale"},{"key":"2477_CR629","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202000515","volume":"7","author":"Q Lv","year":"2020","unstructured":"Lv Q, Cheng L, Lu Y, Zhang X, Wang Y, Deng J, et al. Thermosensitive exosome-liposome hybrid nanoparticle-mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer. Adv Sci. 2020;7:2000515.","journal-title":"Adv Sci"},{"key":"2477_CR630","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nano.2017.09.011","volume":"14","author":"MS Kim","year":"2018","unstructured":"Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen I, Klyachko NL, et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2018;14:195\u2013204.","journal-title":"Nanomedicine"},{"key":"2477_CR631","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01264-5","volume":"20","author":"L Li","year":"2022","unstructured":"Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnology. 2022;20:50.","journal-title":"J Nanobiotechnology"},{"key":"2477_CR632","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2019.12.005","volume":"318","author":"L Zhao","year":"2020","unstructured":"Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J Control Release. 2020;318:1\u201315.","journal-title":"J Control Release"},{"key":"2477_CR633","doi-asserted-by":"publisher","first-page":"23827","DOI":"10.1021\/acsnano.4c09027","volume":"18","author":"F Fang","year":"2024","unstructured":"Fang F, Chen X. Carrier-free nanodrugs: from bench to bedside. ACS Nano. 2024;18:23827\u201341.","journal-title":"ACS Nano"},{"key":"2477_CR634","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117258","volume":"178","author":"J An","year":"2024","unstructured":"An J, Zhang Z, Zhang J, Zhang L, Liang G. Research progress in tumor therapy of carrier-free nanodrug. Biomed Pharmacother. 2024;178:117258.","journal-title":"Biomed Pharmacother"},{"key":"2477_CR635","doi-asserted-by":"publisher","first-page":"14105","DOI":"10.2147\/IJN.S490485","volume":"19","author":"B Lin","year":"2024","unstructured":"Lin B, Lin P, Zhang X, Liao Y, Yu Y, Xu X, et al. Carrier-free, hyaluronic acid-modified self-assembled doxorubicin, and Chlorin e6 nanoparticles enhance combined chemo- and photodynamic therapy in vivo. Int J Nanomedicine. 2024;19:14105\u201324.","journal-title":"Int J Nanomedicine"},{"key":"2477_CR636","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202203019","volume":"34","author":"P Wu","year":"2022","unstructured":"Wu P, Zhang H, Sun M, Mao S, He Q, Shi Y, et al. Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier-Free Nanoassembly of Fluorinated Prodrug and siRNA. Adv Mater. 2022;34:e2203019.","journal-title":"Adv Mater"},{"key":"2477_CR637","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2022.136322","volume":"442","author":"S Wang","year":"2022","unstructured":"Wang S, Bai Y, Wang D, Zhai Y, Qiao Y, Zhao X, et al. Reversing tumor to \u201cHot\u201d: A NIR light-triggered carrier-free nanoplatform for enhanced tumor penetration and photo-induced immunotherapy. Chem Eng J. 2022;442:136322.","journal-title":"Chem Eng J"},{"key":"2477_CR638","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2022.134783","volume":"435","author":"X Chen","year":"2022","unstructured":"Chen X, Zheng R, Zhao L, Kong R, Yang N, Liu Y, et al. Photodynamic therapy initiated immunotherapy of self-delivery re-educator by inducing immunogenic cell death and macrophage polarization. Chem Eng J. 2022;435:134783.","journal-title":"Chem Eng J"},{"key":"2477_CR639","first-page":"220","volume":"8","author":"H Mei","year":"2022","unstructured":"Mei H, Cai S, Huang D, Gao H, Cao J, He B. Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification. Bioact Mater. 2022;8:220\u201340.","journal-title":"Bioact Mater"},{"key":"2477_CR640","doi-asserted-by":"publisher","first-page":"18114","DOI":"10.1021\/acsnano.3c04887","volume":"17","author":"T Zeng","year":"2023","unstructured":"Zeng T, Zang W, Xiao H, Jiang Y, Lin S, Wang M, et al. Carrier-free nanovaccine: an innovative strategy for ultrahigh melanoma neoantigen loading. ACS Nano. 2023;17:18114\u201327.","journal-title":"ACS Nano"},{"key":"2477_CR641","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy A, Bai Z, Satija R, Fan R. The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol. 2023;24:695\u2013713.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2477_CR642","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01941-z","volume":"23","author":"S Lee","year":"2024","unstructured":"Lee S, Kim G, Lee J, Lee AC, Kwon S. Mapping cancer biology in space: applications and perspectives on spatial omics for oncology. Mol Cancer. 2024;23:26.","journal-title":"Mol Cancer"},{"key":"2477_CR643","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41590-023-01678-9","volume":"24","author":"LA Walsh","year":"2023","unstructured":"Walsh LA, Quail DF. Decoding the tumor microenvironment with spatial technologies. Nat Immunol. 2023;24:1982\u201393.","journal-title":"Nat Immunol"},{"key":"2477_CR644","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41568-023-00657-4","volume":"24","author":"N de Souza","year":"2024","unstructured":"de Souza N, Zhao S, Bodenmiller B. Multiplex protein imaging in tumour biology. Nat Rev Cancer. 2024;24:171\u201391.","journal-title":"Nat Rev Cancer"},{"key":"2477_CR645","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41592-024-02243-4","volume":"21","author":"SE Irac","year":"2024","unstructured":"Irac SE, Soon MSF, Borcherding N, Tuong ZK. Single-cell immune repertoire analysis. Nat Methods. 2024;21:777\u201392.","journal-title":"Nat Methods"},{"key":"2477_CR646","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-23-1380","volume":"14","author":"KSS Enfield","year":"2024","unstructured":"Enfield KSS, Colliver E, Lee C, Magness A, Moore DA, Sivakumar M, et al. Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer. Cancer Discov. 2024;14:1018\u201347.","journal-title":"Cancer Discov"},{"key":"2477_CR647","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43201-6","volume":"14","author":"JK Benotmane","year":"2023","unstructured":"Benotmane JK, Kueckelhaus J, Will P, Zhang J, Ravi VM, Joseph K, et al. High-sensitive spatially resolved T cell receptor sequencing with SPTCR-seq. Nat Commun. 2023;14:7432.","journal-title":"Nat Commun"},{"key":"2477_CR648","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"2477_CR649","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02314-y","volume":"21","author":"Y Du","year":"2021","unstructured":"Du Y, Cao J, Jiang X, Cai X, Wang B, Wang Y, et al. Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression. Cancer Cell Int. 2021;21:613.","journal-title":"Cancer Cell Int"},{"key":"2477_CR650","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115945","volume":"44","author":"T Wu","year":"2025","unstructured":"Wu T, Zhao X, Zhang Y, Qiu D, Diao K, Xu D, et al. Precise metabolic dependencies of cancer through deep learning and validations. Cell Rep. 2025;44:115945.","journal-title":"Cell Rep"},{"key":"2477_CR651","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006290","volume":"11","author":"L Magr\u00e9","year":"2023","unstructured":"Magr\u00e9 L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer. 2023;11:e006290.","journal-title":"J Immunother Cancer"},{"key":"2477_CR652","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175:1972-88.e16.","journal-title":"Cell"},{"key":"2477_CR653","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","volume":"183","author":"AE Ringel","year":"2020","unstructured":"Ringel AE, Drijvers JM, Baker GJ, Catozzi A, Garc\u00eda-Ca\u00f1averas JC, Gassaway BM, et al. Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell. 2020;183:1848-66.e26.","journal-title":"Cell"},{"key":"2477_CR654","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41586-024-07529-3","volume":"630","author":"JE Bader","year":"2024","unstructured":"Bader JE, Wolf MM, Lupica-Tondo GL, Madden MZ, Reinfeld BI, Arner EN, et al. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature. 2024;630:968\u201375.","journal-title":"Nature"},{"key":"2477_CR655","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2306776121","volume":"121","author":"J Chen","year":"2024","unstructured":"Chen J, Liu X, Zou Y, Gong J, Ge Z, Lin X, et al. A high-fat diet promotes cancer progression by inducing gut microbiota-mediated leucine production and PMN-MDSC differentiation. Proc Natl Acad Sci U S A. 2024;121:e2306776121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2477_CR656","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.immuni.2024.05.021","volume":"57","author":"RB Delconte","year":"2024","unstructured":"Delconte RB, Owyong M, Santosa EK, Srpan K, Sheppard S, McGuire TJ, et al. Fasting reshapes tissue-specific niches to improve NK cell-mediated anti-tumor immunity. Immunity. 2024;57:1923-38.e7.","journal-title":"Immunity"},{"key":"2477_CR657","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.06.018","author":"CM Phelps","year":"2025","unstructured":"Phelps CM, Willis NB, Duan T, Lee AH, Zhang Y, Rodriguez JD, et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell. 2025. https:\/\/doi.org\/10.1016\/j.cell.2025.06.018.","journal-title":"Cell"},{"key":"2477_CR658","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","volume":"611","author":"JL Galeano Ni\u00f1o","year":"2022","unstructured":"Galeano Ni\u00f1o JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611:810\u20137.","journal-title":"Nature"},{"key":"2477_CR659","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cell.2022.02.027","volume":"185","author":"A Fu","year":"2022","unstructured":"Fu A, Yao B, Dong T, Chen Y, Yao J, Liu Y, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell. 2022;185:1356-72.e26.","journal-title":"Cell"},{"key":"2477_CR660","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/j.cmet.2023.09.011","volume":"35","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yu X, Bao R, Huang H, Gu C, Lv Q, et al. Dietary fructose-mediated adipocyte metabolism drives antitumor CD8(+) T cell responses. Cell Metab. 2023;35:2107-18.e6.","journal-title":"Cell Metab"},{"key":"2477_CR661","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/0008-5472.CAN-22-2405","volume":"83","author":"X Zhang","year":"2023","unstructured":"Zhang X, Cheng L, Gao C, Chen J, Liao S, Zheng Y, et al. Androgen signaling contributes to sex differences in cancer by inhibiting NF-\u03baB activation in T cells and suppressing antitumor immunity. Cancer Res. 2023;83:906\u201321.","journal-title":"Cancer Res"},{"key":"2477_CR662","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01952-x","author":"Q You","year":"2025","unstructured":"You Q, Wu G, Li H, Liu J, Cao F, Ding L, et al. A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy. Nat Nanotechnol. 2025. https:\/\/doi.org\/10.1038\/s41565-025-01952-x.","journal-title":"Nat Nanotechnol"},{"key":"2477_CR663","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01922-3","author":"Y Wu","year":"2025","unstructured":"Wu Y, Chen W, Deng J, Cao X, Yang Z, Chen J, et al. Tumour-derived microparticles obtained through microwave irradiation induce immunogenic cell death in lung adenocarcinoma. Nat Nanotechnol. 2025. https:\/\/doi.org\/10.1038\/s41565-025-01922-3.","journal-title":"Nat Nanotechnol"},{"key":"2477_CR664","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.cmet.2025.03.012","volume":"37","author":"YZ Wang","year":"2025","unstructured":"Wang YZ, Chen WH, Han ZY, Zhang SM, Ji P, Zhang C, et al. Targeted tumor therapy with L-cyst(e)ine-addicted bacteria-nanodrug biohybrids. Cell Metab. 2025;37:1277-93.e8.","journal-title":"Cell Metab"},{"key":"2477_CR665","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41551-021-00807-9","volume":"6","author":"DW Zheng","year":"2022","unstructured":"Zheng DW, Deng WW, Song WF, Wu CC, Liu J, Hong S, et al. Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma. Nat Biomed Eng. 2022;6:32\u201343.","journal-title":"Nat Biomed Eng"},{"key":"2477_CR666","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01904-5","author":"K Zhao","year":"2025","unstructured":"Zhao K, Yan Y, Jin XK, Pan T, Zhang SM, Yang CH, et al. An orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer. Nat Nanotechnol. 2025. https:\/\/doi.org\/10.1038\/s41565-025-01904-5.","journal-title":"Nat Nanotechnol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02477-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:04:59Z","timestamp":1760490299000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02477-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":666,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2477"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02477-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}